Invitation to Autoliv’s Q2 2017 Teleconference

The report will be available at www.autoliv.com under Quarterly Reports. In addition, a teleconference will take place the same day. Time:               14:00 -15:00 CEST (13:00 BST, 08:00 am EDT) Main Speaker:               Jan Carlson, Chairman, President & CEO Attend the Webcast:      Follow the link on our web Attend by phone:          To participate in the Q&A session, please dial in: National free phone - United Kingdom:               0800 279 5004   National free phone - United States of America:  1877 280 1254   National free phone - Sweden:                           0200 883 440                 International Call:                                   +44(0)20 3427 1900                                                Confirmation Code:                               3120943                                                    Audio replay:    An audio replay will be available on the web after the conference until July 27, 2017. Transcript:         Will be available on www.autoliv.com under the Investors section, Presentations & Transcripts. For additional information or details please see www.autoliv.com. Best regards, Anders Trapp V.P. Investor Relations  Phone: +46 (0)8 587 206 71

Farstad Shipping ASA – Mergers completed

Skudeneshavn, Ålesund and Limassol, 21 June 2017 With the completion of the transactions announced in the stock exchange notice dated February 6, today marks the effective conception of the World's largest high-end offshore service vessel (OSV) company, Solstad Farstad ASA. The company has a fleet of 152 OSVs of which 33 are CSVs, 64 PSVs and 55 AHTS. The company is active in all key offshore regions and will operate out of Skudeneshavn, Norway. "Today marks the beginning of a new company based on the proud heritage of three leading OSV companies. Over the last few months, the three organizations have worked together on the closing process and prepared the important integration process. I want to use the opportunity to thank everyone who has been involved and put in a lot of effort over the last months. Now, the real work starts as we need to extract the cost and revenue synergies identified", said Lars Peder Solstad, CEO of Solstad Farstad ASA. The transactions which have been completed today include the mergers between (i) Farstad Shipping ASA and Solship Invest 2 AS with the latter as the surviving entity and with settlement in shares in Solstad Offshore ASA ("SOFF", now renamed Solstad Farstad ASA), (ii) Deep Sea Supply Plc and Solship Sub AS with the latter as the surviving entity and (iii) Solship Sub AS and Solship Invest 3 AS with the latter as the surviving entity and with settlement in SOFF shares, together referred to as the "Mergers". The completion of the Mergers was registered in the Norwegian Register of Business Enterprises after close of trading on the Oslo Stock Exchange today, 21 June 2017. 136,179,139 new SOFF shares have been issued to the former shareholders of Farstad Shipping ASA ("FAR"), while 30,666,339 new SOFF shares have been issued to the former shareholders of Deep Sea Supply Plc ("DESSC"), in exchange for shares they held in FAR and DESSC per the exchange ratios set forth in the plans for the Mergers. Of the new SOFF shares, 16,828,252 were issued to Aker Capital AS ("Aker"), a subsidiary of Aker ASA, in exchange for the 601,009,010 shares in FAR held by Aker. 8,836,681 shares were issued to Ocean Yield ASA ("Ocean Yield"), a subsidiary of Aker, in exchange for the 315,595,760 shares in FAR held by Ocean Yield. 4,470,910 shares were issued to the Farstad family and the related companies Tyrholm & Farstad AS and Tyrholm & Farstad Invest AS in exchange for the 159,675,341 shares they held in FAR. 16,828,252 shares were issued to Hemen Holding Limited ("Hemen") in exchange for the 601,009,009 shares it held in FAR, and 9,636,195 shares were issued to Hemen in exchange for the 91,543,853 shares it held in DESSC. Furthermore, in connection with the completion of the Mergers, 16,000,000 new SOFF shares have today been issued to Hemen in exchange for its cash contribution of NOK 200,000,000 to SOFF, and 20,000,000 new SOFF shares have at the same time been issued to Aker by Aker's exercise of its conversion rights under the convertible loan in the principal amount of NOK 250,000,000 by set-off against the principal amount of that loan, corresponding to NOK 12.50 per share issued to each of Hemen and Aker. In total, the number of issued SOFF shares has increased by 202,845,478 from 88,686,821 to 291,532,299, each with a par value of NOK 2. As a consequence, SOFF's share capital has increased with NOK 405,690,956 from NOK 177,373,642 to NOK 583,064,598. SOFF's articles of association are amended in accordance with the abovementioned. Delivery of the new SOFF shares in VPS will take place on 26 June 2017. First day of trading of the new SOFF shares will be 22 June 2017; however, since trading will begin before delivery of the new shares in VPS, no account-to-account transactions and no transactions with settlement prior to 26 June 2017 will be allowed in the new shares on the Oslo Stock Exchange in this period. As a result of the completion of the Mergers, Farstad Shipping ASA and Deep Sea Supply Plc have been dissolved and removed from listing on the Oslo Stock Exchange.   SOFF's 17,999,444 class B shares have been converted to class A (ordinary) shares, and SOFF now has one single class of shares. Aker's 1,688,050 class B shares accordingly are now also of that single class. SOFF has also as part of the completion of the Mergers issued 1,052,631 warrants to Sagale Beteiligungsverwaltungs GmbH ("Sagale") as replacement of the 10,000,000 warrants it held in DESSC. Each warrant gives the right to subscribe for one share in SOFF for a price of NOK 11.78 per share until 21 July 2019, after which the warrants will automatically lapse without compensation to the holder. Aker now holds 58,496,302 shares, representing 20.1 % of the shares and votes in issue, and Ocean Yield holds 8,836,681 shares representing 3.0 % of the shares and votes in issue. The aggregate holding of Aker and Ocean Yield is 67,332,983 shares, representing 23.1 % of the shares and votes in issue. Hemen now holds 46,961,289 shares, representing 16.1 % of the shares and votes in issue. In addition, Hemen is party to Total Return Swap (TRS) agreements (originally entered into with exposure to DESSC shares) with exposure to 4,496,842 shares in SOFF and with expiration date 26 June 2017 and exercise price NOK 9.979 per share. Upon completion, the Solstad family, through its related companies SOFF Invest AS and Ivan II AS, holds an unchanged number of 21,066,965 shares, representing approximately 7.2 % of the shares and votes in issue. On a consolidated basis, the Farstad family and the related companies Tyrholm & Farstad AS and Tyrholm & Farstad Invest AS together now hold a total of 4,470,910 shares, representing 1.5 % of the shares and votes in issue. None of Aker, Ocean Yield, Hemen, the Farstad family or the Solstad family hold any rights to shares. None of the percentages set forth above reflect the effect of the potential exercise of the warrants issued to Sagale. SOFF's board of directors now consists of Terje Vareberg (Chairman), Toril Eidesvik, Ellen Solstad, Frank O. Reite, Harald Thorstein, Sverre A Farstad and Merete Haugli. Contact: Lars Peder Solstad, Chief Executive Officer of Solstad Offshore ASA at +47 913 18 585 or Sven Stakkestad, Deputy Chief Executive Officer of Solstad Offshore ASA at +47 905 15 802. Karl-Johan Bakken, Chief Executive Officer of Farstad Shipping ASA at +47 901 05 697 or Olav Haugland, Chief Financial Officer of Farstad Shipping ASA at +47 915 41 809. Anders Hall Jomaas, Chief Financial Officer of Deep Sea Supply Plc at +47 400 42 918. This information is published in accordance with the requirements of the Continuing Obligations of the Oslo Stock Exchange.

UTA drives entrepreneurship ecosystem in North Texas

2016 Tech Titans Inventors awardee and University of Texas at Arlington chemistry Professor Purnendu “Sandy” Dasgupta has been described as a “patent-making machine.” But he is more than that.  Three of his inventions are an integral part of chromatograph machines, which are widely used to analyze the content of complex mixtures in fields as varied as forensic testing, doping analysis, pharmaceutical development and even nuclear power. Annual sales of these machines surpass $2 billion worldwide.  “We have developed a very long-term relationship with multinational ThermoFisher Scientific to support taking our discoveries right through to the commercialization phase where they can benefit society,” Dr. Dasgupta said. “They give us continuous financial support, alongside equipment and supplies, and work with us to make these dreams a reality. More than 15 of my inventions are licensed to ThermoFisher Scientific, which also benefits the University financially every year.  “My students also benefit,” he added. “ThermoFisher Scientific has hired and given internships to several of my students, giving them the opportunity to gain experience all across the invention timeline, from discovery to commercialization.”  Dasgupta is not alone in this success. UTA has developed a strong innovation pipeline, with more than 100 patents issued over the last five years and more than 25 technologies licensed to outside companies. Some 60 faculty and students are currently working on start-ups and more than 20 start-up companies are developing around UTA.  “UTA is committed to developing an environment and culture that eliminates obstacles to innovation and entrepreneurship so that results of research and creative activity can be moved from our studios and laboratories into the economy for the benefit of society,” said UTA President Vistasp Karbhari.  “We are actively working with faculty, students, and our own alumni, as well as the community, the city, the chamber of commerce, business accelerators, and potential investors, to build an entrepreneurship culture with the necessary support systems to ensure inventors can really succeed,” he continued.  CULTURE OF INVENTION AND ENTREPRENEURSHIP  UTA has developed a culture that embraces both faculty and student entrepreneurship as elements that coexist and reinforce each other.  Many of UTA’s faculty members have a strong record of success as inventors, so they can pass their experience on to student entrepreneurs looking to take their ideas into the marketplace.  “We now count 12 faculty and top administrators who have been named fellows of the National Academy of Inventors (NAI), an organization that specifically recognizes their capacity to translate inventions into tangible benefits for society,” said Duane Dimos, UTA vice president for research.  “Their inventiveness and that of the faculty and students they attract to the University has become the basis for a wider University entrepreneurship culture that permeates our Strategic Plan 2020: Bold Solutions | Global Impact,” he added. “Leading in creativity, innovation and entrepreneurship is one of our guiding aspirations.”  One of those NAI fellows is Robert Magnusson, UTA’s Texas Instruments Distinguished University Chair in Nanoelectronics and professor of electrical engineering, who broke his own record in 2015 with five patents issued in less than a year and who now holds a total of 20 issued patents, with 13 more pending. He has also successfully translated these inventions into a start-up company, Resonant Sensors, that is having commercial success.  “My idea with my lab is that you can walk in with an idea and walk out with a device,” Dr. Magnusson said. “It is always a cause for celebration when a patent is issued and getting five in short order never happened to me before.”  Another prolific inventor is J.-C. Chiao, UTA’s Janet and Mike Greene Endowed Professor and Jenkins Garrett Endowed Professor of Electrical Engineering, who was recently named a fellow of SPIE, the international society for optics and photonics, in recognition for his achievements in micro medical devices and systems. Dr. Chiao already has 12 issued patents and is another prior Tech Titans Inventors awardee.  This strong culture of innovation is also attracting faculty members who have already been successful in the corporate world. Krish Prabhu, former chief technology officer of AT&T, has taken the post of research professor in the Department of Computer Science and Engineering. Dr. Prabhu oversaw the company’s global technology direction, which includes network innovation, product development and research, intellectual property organization and global supply chain organization.  Other inventors with successful previous careers in business include J.-C. Chaio, who worked for Bell Communications and Chorum Technologies; business professor Kay-Yut Chen, who worked as a principal research scientist at Yahoo Labs; and physics professor Wei Chen, a former senior scientist for Nomadics Inc. who recently developed the advanced grow technology behind the start-up SolGro.  UTA also actively promotes increased innovation among faculty through UTA’s Interdisciplinary Research Program, which provides seed grants for interdisciplinary proposals on a competitive basis. Nine teams have been funded and to date one has presented a patent disclosure for “A System for Neuro Feedback Anger Management to Prevent Domestic Violence,” a systematic method and technology to help individuals control anger responses.  “By taking advantage of the multiple perspectives offered by interdisciplinary research, these teams have proposed new ways of attacking real-world problems, demonstrating yet again the commitment of our faculty to the highest level of scholarship,” Dr. Dimos said.  ENTREPRENEURSHIP ECOSYSTEM  UTA has developed an elaborate entrepreneurship ecosystem to support faculty, students, alumni and community inventors. Specialized curricula, spaces to encourage innovation and interaction among entrepreneurs, support for events and pitch competitions and a very proactive patenting and licensing office with strong links to business accelerators and the investor community all reinforce the ecosystem and contribute to inventors’ success. UTA’s support also extends to prototyping, development and business consulting for start-ups. Curricula UTA has designed curricula addressing creativity, innovation and entrepreneurship that is oriented toward students of all disciplines. The College of Business offers certificates in entrepreneurship that provide any interested student with skills and training in identifying innovations and market opportunities, writing a business plan, obtaining funding and launching a new company—in other words, the basic tools needed to become entrepreneurs.  Courses within the certificate, which can be earned as part of degree programs at the undergraduate and graduate levels, include Entrepreneurship and Venture Management, Entrepreneurship in the Arts, Engineering Entrepreneurship, Social Entrepreneurship and Innovation and Creativity and Entrepreneurship.  Capstone senior design projects are required for all engineering undergraduates prior to graduation. Each project team, made up of five to six senior undergraduate students, is required to take on a real-world engineering problem, often sponsored by a local company looking for expert help. The teams are expected to design, implement, test and provide a final demonstration of a prototype solution, all over a two-semester period.  Chris McMurrough, senior lecturer for the Computer Science and Engineering Department’s (CSE) senior design courses, is a UTA alumnus who teaches by day and runs a robotics start-up at night.  He helped organize the senior design showcase and encourages the students to become entrepreneurs.  “There are 17 CSE teams presenting projects this semester, which is a record,” Dr. McMurrough said. “We teach our students to find opportunities where money can be made and where the opportunities for entrepreneurship are. We also teach them how to manage systems better, which is what companies and public sector organizations are often looking for.”  Among the solutions presented was an app developed for DE-CRUIT, a theater company in New York that supports veterans’ reintegration into society through theater and the arts. The app enables the organization to keep in touch with veterans on any platform—phone, laptop, tablet– and includes an SOS button to link veterans to first-responders 24 hours a day.  Another solution was an electronic “hubodometer” that can be placed inside truck and bus wheels to record motion data that is more accurate than an odometer, which could help improve city management by lowering bus and truck maintenance costs. This particular solution was requested by Fleetwatch, a company that develops fleet management technologies that asked UTA students to solve a specific problem.  Some projects have even been successfully patented. A mechanical engineering senior design project for a smart bandage device that allows more efficient healing of wounds was recently patented with the help of Raytheon, the current employer of the student leader of the team.  “Our goal was to protect the wound and increase infection control,” said team leader and mechanical engineering graduate Letia Blanco, who is now a lead engineer at Raytheon. “Raytheon teamed up with UTA to secure the patent. It’s very exciting.”  The team also included Christopher Alberts, Kyle Godfrey, Andrew Patin and Chris Grace. Panos Shiakolas, associate professor in the Mechanical and Aerospace Engineering Department; and Pranesh Aswath, professor in the Materials Science and Engineering Department and vice provost for academic planning and policy, advised and guided the team to success.  Peter Crouch, dean of the College of Engineering, noted, “These senior design project solutions are among the multiple initiatives we aim to develop across campus to promote entrepreneurship and innovation. Going forward, we will also draw in the local community more in ways that support burgeoning entrepreneurial ideas by both faculty and students.”  Innovation Spaces Spaces also exist within the University to develop ideas. Faculty, staff, students and the community have access to the FabLab in the Central Library, a platform for project-based, hands-on science, technology, engineering, arts and mathematics (or STEAM) education. The UTA FabLab is the first MIT-affiliated FabLab in a university in Texas and enables students to develop a rich toolkit of professional, creative and technological skills.  FabLab students recently surprised 8-year-old Garrett Clark with a custom-built prosthetic arm created at the lab. Garrett, who was born with a partial right arm, is the son of Andrew Clark, an associate professor at the University.  Adam Williams, a senior kinesiology major, was among those who helped design and build the fully functioning prosthetic arm from scratch.  “The ability to think of something and then create it is just a rush,” Williams said. Garrett will continue to visit the FabLab to make regular adjustments to his prosthetic until they are able to make the perfect fit for him.  The StartUp Lounge is a collision space where entrepreneurs can meet and interact.  At the StartUp Lounge, UTA provides workshops and holds interactive discussions on topics that will help entrepreneurs move their business ideas or companies forward. Close to 400 students, faculty and community members have passed through the StartUp Lounge’s EpICMavs and EpICMavs Deep Dive entrepreneurship courses.  EpICMavs is an entrepreneurship workshop series designed by UTA in conjunction with mentors from TECH Fort Worth, a non-profit organization UTA strongly supports that identifies entrepreneurs and start-up companies and coaches them toward success. The current TECH Fort Worth Board of Directors includes Carolyn Cason, UTA’s former vice president of research and a fellow of the National Academy of Inventors, and Lin Nelson, a UTA alumnus with a degree in finance.  EpIC stands for Entrepreneurial, Innovative and Collaborative—which is what UTA stands for. The EpICMavs sessions take place on Wednesday evenings at the StartUp Lounge and are open to faculty, staff, students and the community. Each session focuses on a particular topic of interest to entrepreneurs. The speakers or panelists begin the conversation and the attendees ask questions so everyone benefits from the knowledge and experience of others. Some sessions are hands-on workshops where participants work on their business ideas.  EpICMavs Deep Dive is a seven-week cohort offered twice in the summer that provides UTA students and faculty the opportunity to receive hands-on mentoring while they work on their business ideas. The participants create a value proposition and business model canvas analysis of their business ideas under the guidance of mentors from TECH Fort Worth. Next, participants learn about financials and how to project the company’s needs and expenditures over the first few years of the business. Finally, participants learn how to put together a pitch for any situation. Participants have the opportunity to practice 10-minute pitches and receive valuable feedback from entrepreneur mentors.  UTA alumnus and interdisciplinary studies major Scott Parsinen participated in the StartUp Lounge’s many seminars and events. He has now established Cadmus Dental, a start-up that offers manufacturing of dental devices—crowns, bridges, dentures and implant accessories- for its network members, largely dental laboratories and dentists.  “I was given the opportunity by UTA to start Cadmus Dental at the StartUp Lounge, where I was able to participate in the EpICMavs program for entrepreneurs,” Parsinen said. “I attended the program in both the fall and spring semesters and learned an extraordinary amount from investors, community business leaders and UTA professors.  “Additionally, I was able to network with amazing fellow entrepreneurs and get the support I needed during the difficult start-up process. When starting a company, no matter how much experience you have, there is no greater resource than UTA’s EpIC Mavs,” he added.  Parsinen has also developed additional opportunities for himself and UTA through these relationships. Cadmus Dental now has plans to employ UTA students and offer internships at its new office next to College Park Center. The company is using the online jobs database Hire-a-Maverick and has a growing relationship with the Lockheed Martin Career Development Center to identify potential employees from among UTA students. In addition, Cadmus has entered into a strategic partnership with UTA student-run start-up Neü Robotics to develop Cadmus proprietary intellectual property. Innovation Events and Pitch Competitions UTA supports different ideas competitions and entrepreneurship clubs. The Office of Research sponsors an annual InnovationDay@UTA event for both high school and university students. This year’s event featured a high school and college student “Shark Tank”-style competition, student and faculty start-up pitches and posters and a showcase of community start-up companies and services for entrepreneurs. The 2017 lunch speaker was Michael Chaffin, a business partner of Mark Cuban and UTA alumnus, who discussed his personal experience and offered advice to young entrepreneurs.  Within the College of Liberal Arts, the Art + Art History Department sponsors the Studio: CreaTec Challenge, an ideas competition to encourage student teams to develop viable solutions and sustainable ideas that successfully address the intersection of culture, business, and technology today. The initiative offers more than $10,000 in cash prizes and start-up resources. Activity spurred from this opportunity includes Artopia—a series of art therapy workshops geared toward the service of the veteran population in the DFW region, including methods spreading from collage to gesture-based digital painting.  The student Entrepreneurship Society offers cash prizes in business plan pitch competitions that are open to any student enrolled at UTA, with faculty advisers from the College of Business.  The University also helps fund student and faculty participation in pitch competitions at other universities and even internationally. Last summer UTA participated in the K Start-up Grand Challenge, a pitch competition run by the Korean government, competing with pH sensor technology developed by Dr. Chiao. The UTA team was among those who spent three months at an accelerator in Korea working on their business and making contacts.  UTA philosophy student Tyler Sickels received an honorable mention in the finals of a Texas Christian University Values and Ventures Business Plan competition with SolGro, an agricultural research and manufacturing start-up with technology developed by physics professor Wei Chen. SolGro also won UTA’s Innovation Day Competition and was named to the short list of the National Council of Entrepreneurial Tech Transfer’s (NCET2) top university start-ups for 2017.  UTA start-up AbeXXa Biologics, led by biology professor and associate vice president for research Jon Weidanz, was selected as one of the NCET2 40 “Best University Start-ups 2017.” AbeXXa Biologics is a life science company focused on research and development of novel antibody therapeutics for the treatment of cancer.  Office of Technology Management UTA leads in the policy arena around intellectual property rights and has a very proactive patenting and licensing office. Strong support from President Karbhari, who recently co-led a task-force that recommended a new University of Texas System policy that provides each campus greater autonomy in assigning intellectual property rights, is now making it easier to work with research sponsors to bring inventions to the market.  The Office of Technology Management works with UT System’s Horizon Fund to fund start-up companies on campus and has set up a partnership with a UTA alumna in Silicon Valley to match the technology developed within the University with investors and corporate partners.  This relationship has already succeeded in licensing a chemical process developed by Kevin Schug, UTA’s Shimadzu Distinguished Professor of Analytical Chemistry. This invention safely disposes of controlled substances and other unused medications, and has been licensed to the start-up Medisposal, Inc. in California. Other businesses opportunities are also under development at this time. Prototyping, Development and Business Consulting  Dr. Dimos believes that UTA’s support for entrepreneurs goes way beyond helping them license their technologies or establish new companies.  “Through the University of Texas at Arlington Research Institute (UTARI) and the Texas Manufacturing Assistance Center (TMAC), we provide support for prototyping, development and business consulting right through to the marketing and commercialization of their ideas,” he said. “The Shimadzu Institute for Research Technologies also provides support from basic research to supporting start-ups as they develop their research.”  UTARI provides a rapid, low-cost and reliable transition path for fundamental technologies to go to market.  TechComb LLC is a UTA spinoff company that received an award from the National Science Foundation’s Small Business Innovation Research Program to develop a modular, reconfigurable robot learning kit to increase interest in science, technology, engineering and mathematics among K-12 students. Aditya Das, senior research scientist at UTARI, developed the core technology for this project.  “In the case of TechComb, UTARI is supporting technologies developed at UTA, but the Institute is also very actively supporting alumni and other small companies that need the capacities of a large university to achieve their commercialization goals,” said Mickey McCabe, UTARI’s executive director.  Lumion Labs is owned by UTA alumnus and entrepreneur Scott Evans, who reached into the University to commercialize UTA technologies and who now is in the final stages of testing and evaluating an environmentally friendly field analyzer to measure arsenic levels in water. The analyzer was developed by Dr. Purnendu “Sandy” Dasgupta and Dr. Aditya Das.  Skyven Technologies, a local start-up, joined forces with the University to apply for a grant from the National Science Foundation’s Small Business Innovation Research Program to develop a test model for cost-efficient solar energy technology.  “Skyven Technologies is an example of a start-up partnering with a large university to gain access to equipment and federal funding to develop its proposal and become successful,” Dr. McCabe added. “These three cases—TechComb, Lumion Labs, and Skyven Technology—demonstrate the role of UTA in helping develop the start-up ecosystem and providing resources that enable bringing ideas into the market.”  UTA assists with streamlining the management of start-ups and improving their operational efficiency through TMAC. Its services span the entire innovation timeline, from invention to selling the start-up to outside investors.  TMAC is hosted at UTA and is an affiliate of the Hollings Manufacturing Extension Partnership, a program of the National Institute of Standards and Technology. Over the past five years, TMAC has supported 211 companies, with an economic impact in sales, cost savings and new investments of $238.7 million and more than 1,486 jobs created or retained.  The University’s resources at the Shimadzu Institute for Research Technologies provide important support for start-ups. Currently, two of UTA’s start-ups, AbeXXa Biologics and Resonant Sensors, are housed at the Shimadzu Institute for Research Technologies in the NanoFab building on campus.  The equipment in the Shimadzu Institute labs would be prohibitively expensive for a start-up company to purchase on its own, so having access to this equipment can be key to its development efforts. Companies can submit samples to be analyzed by UTA scientists, or they can visit the lab and be trained to use the instrumentation themselves. Shimadzu leadership has strong experience in both the public and private sectors and offers technical and entrepreneurial advice to companies as needed.  WHY IS THIS IMPORTANT?  UTA stands as an institution that Is rapidly maturing an innovation ecosystem with a robust pipeline of new inventions that are moving out into the market to benefit society.  This ecosystem integrates the development of an innovation culture among faculty and students with specialized curricula and workshops around entrepreneurship. Facets that promote a vibrant entrepreneurial culture on campus and in the broader community include: capstone senior design projects, innovation workspaces, support for innovation events and pitch competitions, a proactive office of technology management with links to the investment community, support for prototyping and development and business consulting for new companies. Many of these resources are also available to UTA’s 200,000 alumni and business leaders and residents of Texas.  “UTA is poised to expand and grow its partnerships with external stakeholders around the world such as government, investors, and entrepreneurs, as well as peer institutions with similar objectives, to become an even stronger force for economic growth,” said President Vistasp Karbhari. “Together we are becoming a major driver for innovation and entrepreneurship in North Texas.”  The variety of approaches and best practices deployed at UTA are a reflection of the sustained diverse history of of the institution and the urban audiences it serves, its increased visibility as a Carnegie Classification Research – 1 University, its ideal location in the heart of the dynamic and thriving Dallas-Fort Worth area, and its pivotal role as one of the largest public research institutions in Texas.  ”Under our Strategic Plan 2020 Bold Solutions|Global Impact, the University aims to be at the vanguard of nurturing budding entrepreneurs who will create products, services and high-quality jobs in our community and contribute to the world through their intellectual talent and unwavering fearlessness,” said President Karbhari.   Some 60 faculty and students are currently working on start-ups and more than 20 start-up companies are developing around UTA, in line with the themes of our Strategic Plan 2020: Bold Solutions | Global Impact. Some of the companies are: HEALTH AND THE HUMAN CONDITION AbeXXa Biologics  John Weidanz, associate vice president for research and professor of biology This start-up life science company is focused on research and development of novel antibody therapeutics for the treatment of cancer. • Winner at Massachusetts Biotechnology Council Innovation Day • Selected as one of the 40 NCET2 “Best University Start-ups 2017”  Medisposal Kevin Schug, Shimadzu Distinguished Professor of Analytical Chemistry  This is an affordable and environmentally responsible chemical process for disposing of controlled substances and other unused medications. • Licensed through the partnership in Silicon Valley TissueGen Kevin Nelson, former assistant professor of bioengineering A cutting-edge absorbable polymer technology that can be used for implantable drug delivery. • R&D 100 Award for Market Disruptor Services Gold Tuevol Therapeutics Frederick MacDonnell, chair of chemistry and biochemistry Tuevol’s ruthenium-based anti-cancer drugs show remarkable selectivity for tumor tissue in vitro and efficacy in regressing tumors in mice. An ongoing large-scale mouse experiment underway at UT Southwestern should provide the necessary data to secure sufficient funding to apply for investigational new drug status with the FDA.  Resonant Sensors Robert Magnusson, Texas Instruments Distinguished University Chair in Nanoelectronics and professor of electrical engineering  Resonant Sensors has developed a technology based on nanostructured resonant sensors illuminated with light which allows pharmaceutical companies to better define the physical properties of drugs under development. Terapio  Sanjay Aswathi, oncologist and former UTA biochemistry research professor This biopharmaceutical company is developing therapeutics based on the RLIP76 protein. SUSTAINABLE URBAN COMMUNITIES Afthon Raheem Bello, post-doctoral research associate in mechanical and aerospace engineering This company addresses the problem of inadequate access to the electrical grid across the developing world by providing consumers with a heat and power generator twice as efficient and at least five times as affordable as any competing product currently available. GLOBAL ENVIROMENTAL IMPACT Bellkim Energy Daejong Kim, associate professor of mechanical and aerospace engineering It designs, prototypes and tests oil-free turbomachinery with non-contact bearings for environmentally friendly energy systems. SolGro UTA philosophy student Tyler Sickels and Wei Chen, physics professor and co-director of the Center for Security Advances via Applied Nanotechnology This agricultural research and manufacturing start-up is working on advanced grow technologies. • Winner, InnovationDay@UTA Pitch Competition • Shortlisted, NCET2 “Best University Start-ups 2017” • Honorable mention, TCU Values and Ventures Business Plan Competition DATA-DRIVEN DISCOVERY  VisioSound Jodi Tommerdahl, associate professor in curriculum and instruction  This software company is developing a Visual Accent Trainer. It will be the first app to focus specifically on helping users obtain a perfect pronunciation of any sound in supported foreign languages, using cutting-edge technology.  Gozova  UTA business management student Goran Krndija, founder and CEO This on-demand application connects a person with a truck on an as-needed basis for moving and hauling larger objects.  SnapRyde UTA alumnus Chetan Kabra; Tulsi Chandwani, UTA computer science graduate student; and UTA alumnus Daniel Paramo This flexible and innovative platform enables users with common destinations to find a ride. SnapRyde uses a custom and highly innovative driver-rider matching algorithm. EXAMPLES OF UTA-GENERATED 

Fabege continues development of Råsunda

It is the four-storey, comb-shaped office building that previously housed both the Swedish Football Association and AIK that is now to be converted for other uses. The building will be given a new façade, making it a welcome addition to an area of the city that is expected to become home to numerous children – considering the large number of residences currently springing up in the immediate vicinity. Moves are also under way to convert the well-known high-rise building known as “the Dallas Skyscraper” into residences; in fact, work has already begun on drawing up the actual plans. - “City district development is all about creating an attractive setting where the people who live, work and spend time in the area can really enjoy their everyday lives. When building a great many residences, offices and commercial premises, it is essential to remember the children. How can we help citizens put together their everyday lives, and where would be good places to establish schools and preschool facilities? In Råsunda, we have worked closely with the city authorities to come up with an excellent holistic solution for a great many people,” relates Klaus Hansen Vikström, Vice President and Director of Business Development at Fabege. The agreement with the City of Solna is set to run for 20 years with a rent of approximately SEK 12.5m per year, and all three of the new facilities are expected to be up and running as early as the start of the autumn school term 2018. The investment amounts to SEK 140m. According to the plans, the building is to fulfil the requirements for environmental certification to BREEAM In-Use, level “Very good”.

New MenaQ7® Vitamin K2 Study Publishes

OSLO, NORWAY and METUCHEN, NJ (June 22, 2017) – A new study1 of hemodialysis patients examined the risk factors and response to Vitamin K2 supplementation, and confirmed this population’s specific need to correct Vitamin K2 deficiency. The study published in BMC Nephrology, and the vitamin K2 used in the study was MenaQ7® Vitamin K2 as MK-7 from NattoPharma. According to the researchers, the scientific data showed that the vitamin K2 intake in hemodialysis patients is estimated to be 40 percent lower than in the healthy individual group. It has been accepted by the European medical society that hemodialysis patients are vitamin K deficient, and they can benefit from vitamin K2 supplementation. However, this aspect had not yet been evaluated in Eastern Mediterranean populations. “NattoPharma was excited to participate in this clinical intervention trial,” says Hogne Vik, chief medical officer of NattoPharma. “We have long recognized the important implications correcting a vitamin K2 deficiency can have on human health, particularly in patient populations who suffer intense vascular calcification as a result of their condition. This study adds to the body of evidence confirming the cardiovascular support MenaQ7® Vitamin K2 as MK-7 provides, and continues to solidify NattoPharma as the global leader in K2 research and development.” The study, based in Lebanon, assessed if there is a correlation between vitamin K status and vascular calcification score in hemodialysis patients, and if K2 supplementation would improve extra-hepatic vitamin K status in this Eastern Mediterranean populations. Fifty hemodialysis patients were enrolled in this clinical study, and received daily 360 μg of menaquinone-7 (MenaQ7®) for 4 weeks. Extrahepatic vitamin K status represented as the level of dpucMGP (dephosphorylated-uncarboxylated matrix Gla protein, or “inactive” MGP, a K-dependent protein) and vascular calcification scores (AC-24) were measured at the beginning and at the end of the vitamin K2 treatment. The main conclusion was that hemodialysis patients have profound vitamin K deficiency as assessed by high dp-ucMGP plasma levels. High dpucMGP level was significantly correlated with high aortic calcification scores and thus can be used as a non-invasive marker for vascular calcifications. According to the researchers, “The daily administration of 360 μg of vitamin K2 (MK-7) decreased dpucMGP by 86 percent after 4 weeks and it was well tolerated. Further studies should be conducted to assess the change in vascular calcifications after an extended duration of therapy.” Reference: Aoun M et al. High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, a pre-post intervention clinical trial. BMC Nephrol. 2017 Jun 7;18(1):191. doi: 10.1186/s12882-017-0609-3. # # # About NattoPharma and MenaQ7® NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com. For more information, please contact: Kate Quackenbush, NattoPharma Director of Communications Phone: 609-643-0749 x 220 E-mail: kate.quackenbush@nattopharma.com

Ahlsell acquires Water & Sewage business with annual sales of SEK 320 million

ViaCon VA started its operations in 2004, and has through several acquisitions established a strong position in Sweden with several major customers in construction and infrastructure. The acquired business has 81 employees at 11 locations in Sweden. Ahlsell intends to continue the business under the ViaCon VA brand, while purchasing, logistics and administration will be gradually integrated after takeover. "The acquisition adds valuable expertise and strengthens our initiatives directed to attractive customer segments within construction and infrastructure. I find an attractive potential in the distribution agreement regarding their advanced geotechnical products, where Ahlsell can strengthen their current distribution capacity in a positive way", says Johan Nilsson, President and CEO of Ahlsell Group. "We are looking forward to the cooperation with Ahlsell and their contribution to our distribution network for geotechnical products where we continue to provide added value through our technical expertise”, says Morten Holum, CEO in Saferoad Group. The purchase price will be approximately SEK 90 million, depending on the final working capital adjustment at closing. The acquisition is expected to have a marginal positive impact on Ahlsell's earnings per share for 2017. The deal is subject to approval by the Swedish Competition Authority and closing is planned for September 2017. For further information, contact:Johan Nilsson, President and CEO, +46 8 685 70 00Anna Oxenstierna, Head of Investor relations, +46 708 15 84 85 This information is information that Ahlsell AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CEST on 22 June, 2017.

Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder

Montreal, Canada, 22 June 2017 — Phase 2 clinical trial data demonstrate that long-acting buprenorphine (CAM2038), a novel subcutaneous buprenorphine depot formulation, produces an immediate and sustained blockade of opioid effects and suppression of withdrawal symptoms in adults with opioid use disorder. Data from the Opioid Challenge Study were presented today at the annual scientific meeting of the College on Problems of Drug Dependence (CPDD), in Montreal, Canada and a manuscript, which is free to access for the next 7 days, was concurrently published in JAMA Psychiatry.   The Opioid Challenge Study was a multisite, double-blind, randomized, inpatient Phase 2 clinical trial involving 47 adults with moderate to severe opioid use disorder. A total of five 3-day test sessions evaluated the response to randomized intramuscular hydromorphone injections (0, 6, and 18mg). After the first 3-day session (i.e., qualification phase), participants were randomized to weekly CAM2038 at 24mg or 32mg, and the assigned CAM2038 dose was given twice, one week apart (Day 0 and 7). Four sets of hydromorphone challenge sessions were conducted after randomization (Days 1–3, 4–6, 8–10, and 11–13) to assess the blockade of subjective opioid effects, including drug liking and high, and suppression of withdrawal symptoms. “CAM2038 produced clinically relevant buprenorphine plasma levels, translating into rapid and sustained opioid blockade and withdrawal suppression, and was well tolerated both systemically and locally,” said Professor Sharon Walsh, Ph.D., Director, Center on Drug and Alcohol Research at the University of Kentucky and investigator in the clinical trial. “As reported in JAMA Psychiatry, trial results suggest that CAM2038 formulations would be effective in reducing illicit opioid use and relapse, while eliminating the risk for misuse and diversion.” The study attained the primary endpoint for both arms of CAM2038 dosing levels by producing an immediate and sustained blockade of hydromorphone effects (liking maximum effect, 24mg, 0.813; p less than 0.001 and 32mg 0.753; p less than 0.001) and suppression of withdrawal (Clinical Opiate Withdrawal Scale, 24mg 0.617; p less than 0.001 and 32mg 0.751: p less than 0.001). CAM2038 produced a rapid rise of buprenorphine in plasma with maximum concentration around 24 hours, with an apparent half-life of 4 to 5 days, and approximately 50% accumulation of tough concentration from first to second dose. CAM2038 was safely tolerated, with adverse events consistent with other trial results. During the study, 38 participants (81%) experienced one of more adverse event, with the most common being constipation (19%), injection-site pain (11%), erythema (9%), headache (9%) and nausea (9%), although most were rated as mild in intensity.  One case of ventricular extrasystoles resulted in discontinuation and another patient exhibited abnormal liver function tests at discharge and was subsequently diagnosed as having hepatitis C; although neither was considered related to CAM2038. These clinical trial results, combined with pivotal Phase 3 results and a long-term safety study, further strengthen the clinical dossier which Camurus and Braeburn Pharmaceuticals are finalizing for regulatory approval in the U.S., Europe and other key markets. About CAM2038 ProductsCAM2038 are investigational weekly and monthly buprenorphine injection depots in late-stage clinical development for the treatment of opioid dependence, as a part of a comprehensive treatment plan to include counseling and psychosocial support. The products are designed for flexible and individualized treatment from initiation and early stabilization to longer-term maintenance therapy, providing sustained buprenorphine release and efficacy for 1-week and 1-month, respectively. Administration by healthcare professionals ensures delivery and medication adherence, while minimizing risks of diversion, misuse, and accidental exposure to children and teenagers. CAM2038 has been successfully evaluated in five Phase 1 and 2 clinical trials, as well as in pivotal Phase 3 efficacy and long-term safety studies. CAM2038 depots are presented ready for use in prefilled syringes for weekly or monthly administration by a healthcare professional as small dose volume (about 0.6 mL) subcutaneous injection though a thin, 23-gauge needle. CAM2038 is developed for room temperature storage, avoiding the need for cold chain distribution and refrigerator storage. No mixing steps or room temperature conditioning is required prior to administration. About Braeburn PharmaceuticalsBraeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com. About CamurusCamurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are created based on our proprietary FluidCrystal® drug delivery technologies with the purpose of delivering improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.  Media contacts: For Camurus:Fredrik Tiberg, President & CEOTel: +46 46 286 46 92fredrik.tiberg@camurus.com Rein Piir, VP Investor RelationsTel: +46 70 853 72 92ir@camurus.com For Braeburn Pharmaceuticals: Sherry Feldberg, MSLGROUP BostonTel: +1 781 684 0770braeburnpharma@mslgroup.com The information was submitted for publication 08:00 CET on 22 June 2017.

Wihlborgs signs lease with Ferrero in Hyllie

Ferrero Scandinavia is famous for brands like Kinder, Nutella and Tic Tac. Ferrero Scandinavia’s headquarters comprising 700 m² is today located in the Scandinavian Center at Anna Lindhs plats in Malmö. Relocation to the new premises in Hyllie is planned for spring 2019. - "We are pleased to continue our rental relationship with Ferrero Scandinavia and to be able to offer them an attractive solution when they need larger premises. In Dungen, they will have state-of-the-art premises close to the Hyllie station and 10 minutes from Copenhagen Airport,” says Anders Jarl, CEO of Wihlborgs Fastigheter. Dungen comprises about 9,000 m2 and previously, the Swedish Customs has signed an agreement for 6,300 m². The top floor with its own roof terrace is still available, as is part of floor 4 where Ferrero Scandinavia will move in. In Hyllie, Wihlborgs also builds the Origo office building, which will be completed in 2019 as well. Read more about the project at https://www.wihlborgs.se/dungen Wihlborgs Fastigheter AB (publ) For further information, please contact:Anders Jarl, CEO, +46 (0)40 690 57 10Mikael Strand, Regional Director, +46 (0)40 690 57 05 Wihlborgs Fastigheter AB (publ) är ett fastighetsbolag med fokus på kommersiella fastigheter i Öresundsregionen. Fastighetsbeståndet finns i Malmö, Helsingborg, Lund och Köpenhamn.I Malmö, Lund och Helsingborg är Wihlborgs det ledande fastighetsbolaget.Fastigheternas bokförda värde uppgår till 33 mdkr med ett årligt hyresvärde om 2,4 mdkr.Wihlborgs är noterat på Nasdaq Stockholm, Large Cap.

Securitas is taking the security industry into the future

Security is changing and so is Securitas. Changing to better serve our customers and innovating to put technology to the best use possible. This also means opening up, putting our innovation on the outside instead of the inside, showcasing our ideas rather than hiding them away. This is why we created Securitas Future Lab, www.securitasfuturelab.com - a collection of the best thinking and new concepts from every corner of Securitas’ global organization. Some of these ideas and concepts already exist, while others are still in their infancy. We want to share our ideas with the world, with our customers, our partners and the industry at large, because we know that ideas always grow and improve when they are shared and discussed. We will regularly publish new ideas and stories on our Future Lab website, www.securitasfuturelab.com. Make sure to subscribe so you don’t miss any news.    To start with, we have published stories about the security officer of tomorrow and how technology will positively affect the important work a security officer is doing. There are also stories about how drones can support the security services delivered to the customers. Securitas is also updating our brand concept and our visual design to a more modern, bold and vivid look. This will be realized and implemented in the organization worldwide during the coming months. This press release is also available at: www.securitas.com Information: Gisela Lindstrand, Senior Vice President Corporate Communications and Public Affairs, Securitas AB, mobile +46 70 287 8662, or email gisela.lindstrand@securitas.com Securitas is a global knowledge leader in security. We base our protective services on customer-specific needs through different combinations of on-site, mobile and remote guarding, electronic security, fire and safety and corporate risk management. Everywhere from small stores to airports, our 335 000 employees are making a difference.

PARETO ADVISES HOIST GROUP ON THE SUCCESSFUL PLACEMENT OF A SEK 500 MILLION SENIOR SECURED BOND

Pareto Securities AB has advised Hoist Group Holding Intressenter AB (publ)[1] .docx#_ftn1) (together with its subsidiaries, “Hoist Group”), EMEA’s leading technology partner to the hospitality industry, on placing a senior secured bond of SEK 500 million within a framework of SEK 1,000 million (the “Bonds”). The Bonds, maturing in June 2021, will bear a floating rate coupon of 3 month Stibor + 5.00 per cent, with interest paid quarterly in arrears. The proceeds from the transaction will be used to refinance existing bank debt and shareholder loans and to support the continued development of the business. The Bonds contain a portability feature to allow for a change of ownership without triggering a change of control event. The transaction was well received by the market, with participation primarily from Nordic institutional accounts coupled with additional demand from continental Europe. Altogether, more than 40 investors participated in the oversubscribed bond issue. Pareto Securities AB acted as Coordinator & Joint Bookrunner in connection with the bond issue. For more information please contact: Mats Carlsson, CEO, at +46 8 402 52 86 Markus Wirenhammar, Head of Debt Capital Markets, at +46 8 402 51 86 or mw@paretosec.com Hoist Group is the complete hospitality partner for hotels, healthcare institutions and public operations. With more than 20 years of proven hospitality experience, Hoist Group is the market leader in innovative High Speed Internet Access, Conference services, TV & Content solutions, PMS and back-office software as well as other guest-facing amenities. Many hotel chains, flagship independent hotels and public hospitals have entrusted their IT to Hoist Group. Based in Sweden, the company has offices in a total of 18 countries in the EMEA region.                                 ---------------------------------------------------------------------- [1] .docx#_ftnref1) Pending change of name from Goldcup 13961 AB (publ).

Alfa Laval starts signing frame agreements for PureBallast

“We have for some time seen an increased activity and interest in our ballast treatment systems” says Peter Leifland, President of Alfa Laval’s Marine Division. “These two frame agreements confirm that the market has started to move and that ship-owners find Alfa Laval PureBallast a proven and attractive system”. Alfa Laval PureBallast, developed in co-operation with Wallenius Water, was the first chemical-free solution for ballast water treatment certified by IMO (the International Maritime Organization) and one of the first systems to receive the US Coast Guard type approval for usage in all water salinities, including fresh water. The Ballast Water Convention was ratified in September last year and it will enter into force September 8, 2017. From this date newly built vessels must have a ballast water treatment system installed, while existing vessels need to install a ballast water treatment system at the time of their next dry-dock. Ships normally dry dock every fifth year.   Did you know that... Alfa Laval expects that 20 000 ships will retrofit a ballast water treatment system between 2017 and 2025?  About Alfa Laval                                                                                                         Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling. The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval’s products are also used in power plants, aboard ships, oil and gas exploration, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications. Alfa Laval’s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena. Alfa Laval is listed on Nasdaq OMX, and, in 2016, posted annual sales of about SEK 35.6 billion (approx. 3.77 billion Euros). The company has about 17 000 employees. www.alfalaval.com  For more information please contact:Peter TorstenssonSenior Vice President, CommunicationsAlfa LavalTel: + 46 46 36 72 31Mobile: +46 709 33 72 31Gabriella GrotteInvestor Relations ManagerAlfa LavalTel: +46 46 36 74 82Mobile: +46 709 78 74 82

Significant increase of Keliber’s mineral resources

During the summer 2016 and winter 2016 – 2017, Nordic Mining’s associated company Keliber Oy has conducted drilling at the Rapasaari and Syväjärvi lithium deposits. As a result of the drilling programs, the measured and indicated mineral resource estimates in accordance with the JORC code (2012 Edition) have increased by 2.08 million tonnes (35%) compared with the previous March 2016 estimate.  Keliber's new mineral resource estimates, using a 0.50% Li2O cut-off grade, are presented in the table below: (million Länttä  Syväjärvi  Outovesi  Rapasaari  Leviäkangas  Emmes  Total   tonnes)Resourcecategory:     0.437 0.810 - - - - 1.247Measured     0.910 1.160 0.282 3.456 0.190 0.820 6.818IndicatedTotal  1.347  1.970  0.282  3.456  0.190  0.820  8.065 Ore grade 1.06 1.24 1.43 1.15 1.14 1.40 1.19(Li2O %)      - - - - 0.300 -Inferred The mineral resource estimates have been prepared by Markku Meriläinen (MAusIMM) and Pekka Lovén (MAusIMM (CP)). The ore reserve estimates will be updated in connection with the ongoing definitive feasibility study (DFS) for Keliber’s lithium project. Further drilling will continue in the Rapasaari area till the end of June 2017 and subsequently exploration will target other prospective areas. Keliber’s press release and further information of exploration activity is available at www.keliber.fi. For questions, please contact CFO Lars K. Grøndahl, telephone +47-90160941.Oslo, 22 June 2017Nordic Mining ASANordic Mining ASA (www.nordicmining.com)Nordic Mining ASA (“Nordic Mining” or “the Company”) is a resource company with focus on high-end industrial minerals and metals in Norway and internationally. The Company’s project portfolio is of high international standard and holds a significant economic potential. The Company’s assets are in the Nordic region.Through the subsidiary Nordic Rutile AS Nordic Mining is undertaking a large-scale project development at Engebøfjellet in Sogn and Fjordane where the Company has rights and permits to a substantial eclogite deposit with rutile and garnet. Permits for the project have been granted by the Norwegian government. Nordic Mining has rights for exploration and production of high-purity quartz in Kvinnherad in Hordaland and develops the project through its subsidiary Nordic Quartz AS. Nordic Mining’s associated company Keliber Oy in Finland plans to start mining of lithium bearing spodumene and production of lithium carbonate. Nordic Mining holds exploration rights on the Øksfjord Peninsula in Troms and Finnmark, where the Company has discovered a prospective area of sulphide mineralisation. Through the subsidiary Nordic Ocean Resources AS, Nordic Mining is exploring opportunities related to seabed mineral resources.Nordic Mining is listed on Oslo Axess with ticker symbol “NOM”.

SKF enters the world of manufacturing using world-class digital technology

Gothenburg, Sweden 22 June, 2017: SKF's operations in Sweden are set to be given a boost with the inauguration of a completely new, fully-automated and digital production process in Gothenburg, adapted for the manufacture of spherical roller bearings. The new production unit is the first of its type to be put into operations within the SKF Group and is part of a programme of next generation manufacturing technology within the company. "The production flow is totally unique within the bearings industry, and constitutes a new manufacturing standard for us, which we will replicate into numerous facilities within the Group. The investment programme is important for us if we are to utilise our manufacturing capacity even more efficiently, as well as increasing our global competitiveness and the flexibility we can offer our customers," says Luc Graux, Director of Manufacturing for the SKF Group. Using the help of digital technology, the entire value chain in the production process is connected, from the inflow of input components to the delivery of the product to the end user. In addition, the next generation of mobile infrastructure is combined with the manufacturing process, in order to enhance efficiency. "The new production unit will open up new possibilities for us to reduce lead times and to improve flexibility and efficiency in our production," says Sten Karlsson, project manager for the new production unit. Parallel to the investment in Gothenburg, similar investments are planned for Schweinfurt in Germany and Flowery Branch in the USA. Over a million bearings per year are manufactured in the Gothenburg facility. The majority of these are exported. The products are used in heavy industry, such as mining, steelworks, paper machines, wind turbines, train gearboxes, fans and pumps.  

Stora Enso’s SC paper machine (PM8) at Kvarnsveden Mill in Sweden shut down

In February 2017, Stora Enso announced that it planned to permanently shut down paper machine 8 (PM8) at Kvarnsveden Mill in Sweden due to structural weakening of magazine paper demand in Europe. Co-determination negotiations with employees at the mill are still ongoing, but PM8 was permanently shut down yesterday. The number of people affected by the reorganization of the mill and shutdown will be determined during Q3 2017.PM8 had an annual capacity of 100 000 tonnes of super-calendered uncoated magazine paper (SC). The closure of PM8 at Kvarnsveden Mill will not impact Stora Enso’s SC paper offering. In Europe, Stora Enso continues to produce SC paper at Kvarnsveden Mill PM12 as well at Maxau Mill in Germany and Langerbrugge Mill in Belgium. The group also serves its SC customers from Dawang Mill in China. Production at Kvarnsveden Mill will continue on two lines, PM10 for improved newsprint paper and PM12 for SC papers. Stora Enso will make every effort in co-operation with the local community to help the affected personnel find new employment opportunities, and mitigate the impact of the reorganisation and PM8 closure through individual solutions. All job openings in other Stora Enso units will be available to those affected.For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228Liisa Nyyssönen, SVP Communications, Paper division, tel. +358 40 544 3491 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil-based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 25 000 people in more than 35 countries, and our sales in 2016 were EUR 9.8 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

Finland surprises with wide range of intelligent vehicle and mobility solutions – first MaaS solution testing starts in the UK

Finland is known as an internationally unique information-based testing area for intelligent transportation systems. The Aurora test ecosystem in Finnish Lapland enables testing of various digital transport infrastructure (DTI) and connected cars initiatives, as well as autonomous driving and Mobility as a Service (MaaS) in which all major transport needs are met over one interface. The concept of Mobility as a Service is currently live and in use in Helsinki, Finland and is also being tested by travelers in the West Midlands in the UK. The pioneering service, the Whim application by the Finnish operator MaaS Global, will start its trial phase in UK in June. “Our purpose is to offer a real alternative to owning a private car. The Whim application allows people to fulfill all their travel needs with just one application, combining all the modes of transportation into one. With one monthly fee, users can use public transport, taxis or hire a car”, says Kaj Pyyhtiä, the Co-Founder and CXO of MaaS Global. Also the global players in the vehicle and mobility field have noticed Finland’s expertise and see Finland as an attractive investment target. In a recent funding round, MaaS Global raised over 10 million euros. The round was led by Toyota and its insurance partner Aioi Nissay Dowa. Unique smart solutions for vehicles Finland’s solid track record in telecommunications innovations and the high-tech startup scene have introduced several new technologies and digital services to the global market. “Finnish companies deliver innovative and secure solutions in connectivity, user experience and service design providing the needed edge for tomorrow’s mobility. Our strong connectivity and mobile background has also inspired Finnish startups to create new solutions that can be utilized in vehicles and enrich the auto industry”, says Mikko Koskue, Intelligent Vehicle and Mobility Solutions Program Director at the Finnish Trade Organisation Finpro. One example is Koru that specializes in wearables and smart car keys for the automotive industry. Koru has developed the smallest, fastest and most flexible platform for user interface creation that enables a smartphone-like experience in-car with fraction of the cost. “We empower brands by providing a customized and connected digital experience platform for cars from smart keys all the way to digital dashboards”, tells Christian Lindholm, CEO of Koru. Valmet Automotive is a good example of the Finnish engineering capabilities and strong manufacturing knowhow. Awarded best partner for Mercedes-Benz Cars in 2016 by Daimler, Valmet Automotive proves how continuous effort and aspiration yields result. With over 4,000 employees globally, Valmet Automotive offers services from concept engineering to complete manufacturing of vehicles and components. “Our core competence is planning the manufacturing of customer vehicles and contributing to the intelligent mobility of tomorrow. We support in finding the manufacturing solutions flexibly and cost-efficiently innovating together for our customer," says Matti Räsänen, Sales and Marketing VP at Valmet Automotive. We welcome you to hear more about Finland’s interesting offering on 28th June at the Finnish Residence in London. Frost & Sullivan’s annual Intelligent Mobility Event organized together with Finpro, offers an opportunity to meet with leading intelligent mobility solution providers from Finland. Altogether 14 Finnish companies are present at the event: Helsinki Business Hub, Siili Solutions, Symbio, Valmet Automotive, Tuup, Futurice, Link Motion, MaaS Global, Tuxera, Nokia, ADA Drive, Foreca, Koru and Flowenum.

Invitation to the presentation of Gjensidige’s results for the 2nd quarter

Gjensidige Group (OSE:GJF) will publish the results for the 2nd quarter on 14 July at 7.00 CET. 14 July (Oslo)CEO Helge Leiro Baastad and CFO Jostein Amdal will present the results via webcast and conference call. 9.00 CETCombined webcast and conference call with presentation of the results. The presentation will be held in English followed by a Q&A session. The webcast can be viewed live on www.gjensidige.no/ir. Participants who would like to ask questions should dial in using one of the telephone numbers below. A replay of the presentation and Q&A session will be made available on www.gjensidige.no/ir. Dial-in details for the Q&A session: Conference ID: 6629876Norway: +47 800 51084UK/ Europe: +44 (0) 800 279 7204USA: +1 (1) 866-548-4713 Other locations: Choose one of the above Confirmation code: 6629876 A replay is available from 14 July at approx. 12.00 CET.Replay phone number: +47 23 50 00 77Replay passcode: 6629876 The full presentation can also be listened to live by dialling in using the same details as above. 10.30 CETCFO Jostein Amdal will be available for a Q&A session for investors and sell-side analysts at Gjensidige’s head office, Schweigaards gate 21 in Oslo. If you wish to attend the Q&A session please register by e-mail to ir@gjensidige.no by the end of business day 13 July. For more information about Gjensidige, please visit www.gjensidige.no/group. Contact persons, Gjensidige Forsikring ASA:Head of Investor Relations: Janne Flessum, tel.: +47 915 14 739Head of Media Relations: Øystein Thoresen, tel.: +47 952 33 382

International sports retailer Stadium upgrades to IFS Applications 9 to power its continued growth

Stadium is a growing sports retail chain in Northern Europe with more than 160 stores located in Sweden, Germany, and Finland, in addition to growing e-commerce sales. Stadium has been using IFS Applications since 2000 and is running a modern retail and supply chain solution along with complete and fully integrated functionality for financials, purchasing, and sales. The company has been growing rapidly and recently entered the German market with three new stores. To support its ambitious growth strategy, Stadium has decided to upgrade to IFS Applications 9. Stadium will be leveraging some of the new features of IFS Applications 9, including the layered application architecture and the role-based IFS Lobby interface. The layered application architecture enables Stadium to adapt IFS Applications code significantly quicker, based on changing needs in the market. It will also make future upgrades easier and reduce the Total Cost of Ownership. In addition to the upgrade, Stadium will also deploy new e-invoicing capabilities for approximately 500 users managing over 500,000 external and internal invoices on an annual basis. “By upgrading to IFS Applications 9, we will have a more flexible solution in place to support our international growth and increasing online sales,” Stefan Maxeby, IT Director at Stadium said. “By using the new IFS Lobby and the layered application architecture, we will enable our staff to work more effectively and make future customizations and upgrades more time- and cost-effective. IFS’s solution also shows strong support for personalization of customer offers and omnichannel, which are two key areas for us. We look forward to a rapid and efficient implementation project and to continuing to grow the business with the support of a robust ERP solution.” Glenn Arnesen, CEO of IFS in Scandinavia, said, “I am pleased to continue our long-standing partnership with Stadium, a highly respected brand in Northern Europe. IFS’s flexible architecture and robust industry functionality keep attracting growing retail companies. We look forward to working with Stadium as we continue to focus on developing IFS’s offering for the retail sector.” For more information about how IFS supports retail companies, visit www.ifsworld.com/corp/industries/retail/.

Nordic Nanovector ASA: Mandatory notification of trade - primary insider

On 22 June 2017, Luigi Costa, the CEO of Nordic Nanovector ASA, purchased 2,000 shares in the company at an average share price of NOK 85.97 per share. Following this transaction, Luigi Costa owns 81,115 shares in the Company and holds 1,338,106 options. This information is subject to duty of disclosure pursuant to Section 4-2 and Section 5-2 of the Norwegian Securities Trading Act. About Nordic NanovectorNordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com

YIT starts the construction of apartment building projects in Helsinki and Espoo, Finland

YIT starts the construction of apartment building projects in Kuninkaantammi, Helsinki and Mankkaa, Espoo, Finland. The combined value of the projects is approximately EUR 25 million and each project will comprise approximately 50 apartments. The start-ups are recorded in the second quarter. Asunto Oy Helsingin Talvitammi is located in the new residential area of Kuninkaantammi close to the Central Park. The apartments vary from two room apartments to terraced houses with a terrace and an own yard. Some of the apartments include a workspace with an additional separate entrance. Parking is located in the garage on the basement floor. The project will be completed in spring 2019. Asunto Oy Espoon Klovinkukkula apartment building is located on the side of a peaceful detached house area near good connections. Some of the apartments come with a bright rooftop terrace. Services are located a short distance away and there are many schools and day care centres in the area. The project will be completed in autumn 2018. The apartments are currently at the pre-marketing stage. Visit YIT’s Homes website to read more about Talvitammi  and Klovinkukkula  (in Finnish). For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi    Esa Turkka, Unit Director, YIT Construction Ltd., tel. +358 40 551 5945, esa.turkka@yit.fi YIT CORPORATION Hanna JaakkolaVice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT creates better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life in sustainable cities. We want to focus on caring for customer, visionary urban development, passionate execution and inspiring leadership. Our growth engine is urban development involving partners. Our operating area covers Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2016, our revenue amounted to nearly EUR 1.8 billion, and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki. www.yitgroup.com

A waiver from Nordea Bank was received on expected breaches of loan covenants as of 30 June 2017

Nordea Bank has approved a waiver request from the Finnish subsidiary Endomines Oy relating mainly due to an expected breach on the ebitda-covenant. Finnvera, as guarantor, has given its consent to this waiver. Terms and conditions in the loan agreement remain thereby unchanged. Total bank loans from Nordea amount to 7.3 MEUR or 71 MSEK, of which guaranteed by Finnvera is 3.6 MEUR or 35 MSEK. Loan repayments will begin in 2018. The loan agreement includes a number of ordinary financial loan covenants to be fulfilled by either Endomines Oy or Endomines AB, unless waived by the bank and the guarantor. Contact personSaila Miettinen-Lähde, CEO, +358 40 548 36 95, saila.miettinen-lahde(at)endomines.com   This information is information that Endomines AB is obliged to make public pursuant to the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on June 22, 2017.   About EndominesEndomines is a gold concentrate producer with mining, development and exploration operations in Eastern Finland along the 40 kilometer long Karelian Gold Line. Through various regulatory approvals, Endomines controls the exploration rights to this entire area. Endomines vision is to participate in the future structural transformation and consolidation of the Nordic mining industry. The Company may therefore be involved in acquisitions of interesting deposits or companies, should such opportunities arise. The shares trade on Nasdaq Stockholm (ENDO) and Nasdaq Helsinki (ENDOM).

Lemminkäinen to build the Logomo pedestrian bridge in Turku, Finland

LEMMINKÄINEN CORPORATION           INVESTOR NEWS         22 JUNE 2017 AT 11 A.M.  LEMMINKÄINEN TO BUILD THE LOGOMO PEDESTRIAN BRIDGE IN TURKU, FINLAND  Lemminkäinen and the City of Turku have signed an agreement for the construction of the Logomo pedestrian bridge in Turku. The construction work will begin in August 2017, and the bridge will be ready for use in autumn 2018. The value of the contract is approximately EUR 9 million.  The contract includes the construction of a pedestrian bridge above the railway yard at the main railway station in Turku. The covered, glass-walled steel bridge will be suspended from five supports. Once completed, it will improve pedestrian connections to Ajurinkatu street, the Ratapihankatu parking facility, the station platforms and the Logomo cultural event centre.   LEMMINKÄINEN CORPORATIONCorporate Communications  ADDITIONAL INFORMATION:Harri KailasaloExecutive Vice President, Infra projectsTel. +358 (0)2071 53394harri.kailasalo@lemminkainen.com  DISTRIBUTION:Key mediawww.lemminkainen.com  Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and the 4,700 professionals we employ, we build a sustainable society. In 2016, our net sales were EUR 1.7 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com 

Volvo Buses receives order for 13 electric buses from Malmö in Sweden

“It’s really gratifying that one of Malmö’s main routes will now be completely electrified with our quiet and exhaust-free electric buses. Electrically powered bus operations contribute to a far better environment for everyone who lives, travels or spends time in the city, and this is a trend we naturally want to boost,” says Jörgen Sjöstedt, head of Volvo Buses on the Nordic market. “It’s also highly significant that we are yet again delivering to Nobina, to whom we have been supplying buses for more than 80 years. Nobina is one of our most important partners.” The new buses are of the Volvo 7900 Electric model. They use about 80 per cent less energy than corresponding diesel buses and will be powered by green electricity to minimise environmental and climate impact. The bus batteries will be fast-charged at the route’s end stops, a process that takes between three and six minutes. The buses will run on route 7 in the city of Malmö, a distance of 14.7 km. Volvo’s electric buses recently started operating in the city of Differdange in Luxemburg. In addition to the all-electric Volvo 7900 Electric, the Volvo Buses range of electrified vehicles encompasses hybrid buses and electric hybrid (plug-in hybrid) models. All told the company has sold more than 3500 electrified Volvo buses globally. Volvo 7900 Electric ·  Fully electrically powered, two-axle, 12 metre long city bus with low floor and three door openings. ·  80 % lower energy consumption than a corresponding diesel bus. ·  Quiet, exhaust emission-free. ·  Equipped with electric motor and lithium-ion batteries. ·  The batteries are charged at the end bus stops in three to six minutes *. ·  Charges via the open interface OppCharge (opportunity charging), which follows the ACEA (European Automobile Manufacturers Association) recommendations. *Charging time varies with topography, load and climate conditions.

PARETO ADVISES VOSTOK NEW VENTURES ON THE SUCCESSFUL PLACEMENT OF A SEK 600 MILLION SENIOR UNSECURED BOND

Pareto Securities AB has advised Vostok New Ventures Ltd., an investment company focused on online marketplaces and businesses with strong network effects, on placing a senior unsecured bond in an amount of SEK 600 million within a framework of SEK 800 million (the “Bonds”). The Bonds, maturing in June 2020, will bear a fixed rate coupon of 5.50 per cent, with interest paid quarterly in arrears. The proceeds from the transaction will be used for general corporate purposes, including investments. The transaction was very well received by the market, with participation primarily from Norwegian and Swedish institutional accounts. Altogether, more than 60 investors participated in the oversubscribed issue, which was upsized by SEK 100 million in response to strong demand. Pareto Securities AB acted as Sole Bookrunner in connection with the bond issue. For more information please contact: Mats Carlsson, CEO, at +46 8 402 52 86 Markus Wirenhammar, Head of Debt Capital Markets, at +46 8 402 51 86 or mw@paretosec.com Vostok New Ventures Ltd, formerly Vostok Nafta Investment Ltd, is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects. The Swedish Depository Receipts (SDRs) of Vostok New Ventures are listed on Nasdaq Stockholm, Mid Cap segment, with the ticker VNV SDB. For more information on Vostok New Ventures, visit www.vostoknewventures.com.        

Presence of protein important clue to tumour regression in neuroblastoma

Neuroblastoma is the third most common form of childhood cancer and causes almost 15 per cent of all cancer-related deaths in children. This high mortality fully reflects both the aggressive nature of the disease and that it often gives rise to secondary tumours (metastases). Paradoxically enough, neuroblastoma also has the highest spontaneous regression frequency of all tumoural diseases. In the present study, the researchers showed that absence of KIF1Bβ contributes to normal neuroblasts not maturing into nerve cells and to a more immature neuroblastoma with a poorer prognosis. “Our study shows that unimpaired maturing of neuroblasts is a basic prerequisite for spontaneous regression of neuroblastoma. What is behind this regression is unknown, but our study is an important piece in the jigsaw for understanding the mechanisms that cause this phenomenon. Understanding this process in greater detail can provide clues for the development of new therapies. For example, it would be interesting to increase levels of KIF1Bβ activity to see if this facilitates, or even induces, tumour regression,” comments Susanne Schlisio, researcher at KI’s Department of Microbiology, Tumor and Cell Biology and at Ludwig Institute for Cancer Research Ltd. High gene expression of the NGF receptor TRKA correlates well with good prognoses and with spontaneous regression of the tumour. Conversely, low levels of Trka, partnered with loss of the 1p36 chromosome locus and amplification of the MYCN oncogene, are associated with poor prognoses. “We have previously shown that the kinesin protein KIF1Bβ, which is present on chromosome 1p36, is a candidate tumour suppressor and that a low expression is correlated with lower survival of neuroblastoma patients,” says Schlisio. The research is being financed with funding from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Paradifference Foundation and the Gösta Fraenckel Foundation for Medical Research. Publication “Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ mediated transport of TRKA” , Stuart M. Fell, Shuijie M. Li, Karin Wallis, Anna Kock, Olga Surova, Vilma Rraklli, Carolin S. Höfig, Wenyu Li, Jens Mittag, Marie Arsenian Henriksson, Rajappa S. Kenchappa, Johan Holmberg, Per Kogner and Susanne Schlisio, Genes and Development, online 21 June, 2017/297077 For more information about the research, please contactSusanne Schlisio, researcherThe Department of Microbiology, Tumor and Cell BiologyKarolinska InsitutetThe Ludwig Institute for Cancer Research Ltd.Tel: + 46 (0)8 524 87117

Concentric AB awarded Hydraulic systems business worth MSEK 65 with leading OEM of heavy trucks

A leading global manufacturer of heavy trucks has recently nominated Concentric AB to manufacture motor pump units for the steering system on their next generation commercial vehicles. Production commenced during the second quarter of 2017 and is expected to reach mature volumes in 2018, generating annual revenues of approximately MSEK 13 across Europe. The total sales value over the lifetime of the contract is estimated at EUR 6.5 million (SEK 65 million) and will be serviced exclusively from Concentric’s facility in Hof, Germany. Concentric’s motor pump units have been introduced on the emergency steering circuit of all of this OEM’s heavy trucks with twin front axle steering. The product has been specifically developed to protect the units against both dust and high pressure water ingression, which allows them to be mounted on the under carriage of the vehicle without the need for a separate water tight enclosure.  The unit can be coupled with a variety of Concentric gear pump types, including the CALMA series pumps with low noise characteristics. The Concentric electro hydraulic unit replaces the power take off pump, providing power on demand which reduces both parasitic losses and the total fuel consumption. Bespoke customer solutions, such as this one, illustrate our future growth strategy to provide unique hydraulic systems which offer fuel savings, cost optimisation and weight savings. “Concentric has continued to deepen relationships with key strategic customers in this end-market sector and we anticipate these relationships to develop further on the next generation of commercial vehicle platforms,” said Oliver Percival, Vice President of Sales. Concentric AB is an innovator in flow control and fluid power, supplying proprietary systems and components to the world’s truck, agricultural machinery, construction equipment and industrial applications end-markets.  The company has manufacturing facilities in the UK, USA, Germany, Sweden, India, China and Argentina. For further information on this product please contact Oliver Percival at oliver.percival@concentricab.com.

Clavister appoints John Vestberg as Acting CEO and Viktor Kovács has been appointed Deputy Chairman of the Board of Directors

Clavister (Nasdaq: CLAV) today announced that Johan Öhman has, at his own request, decided to step down from his role as CEO and President of Clavister. Öhman has led the company through a necessary transformation process over the past months. ”Clavister is a very exciting company, and I’m delighted to have had the opportunity to be part of a challenging but rewarding episode of Clavister’s journey. Now, with the progress we’re experiencing, especially within the service provider segment, being a highly specialized and technology-demanding market, I’ve concluded that the company needs another type of leadership”, says Johan Öhman. John Vestberg, co-founder and current CTO of Clavister, will assume the role as Acting Chief Executive Officer, effective immediately. Vestberg co-founded Clavister in 1997 and was imperative in the process leading up to the release of the company's first commercial security product, as well as a key driver in securing business with some of Clavister's most important strategic accounts. The Clavister Board of Directors has also appointed Viktor Kovács as deputy Chairman of the Board. Kovács has significant and global experience in strategy design and implementation in developing companies in the ICT sector and has had key roles in EDS Corp. (now HP), Cisco, and others. Kovács will have a strong operational supporting role in progressing Clavister. “Clavister is on the brink of a commercial breakthrough, with key customer contracts being developed over the past year. I’m excited to see our new management, with a strong market and product knowledge, combined with seasoned management and marketing skills, start building this business to the next level. I want to thank Johan for his commitment and hard work during his period as CEO, and I wish him all the best for the future”, concludes Björn Norrbom, Chairman of the Board.  --Ends

This is Vanlead Group – Enviro's Chinese partner

Guangzhou Vanlead Group is a state-owned large industrial enterprise in Guangzhou. Founded in 2001, Vanlead specializes in the fields of rubber tyre, salt chemical and fine chemical with distinct regional and industrial advantage. In the middle of June, Enviro made another visit to China to continue planning and discussing issues related to the establishment of a recycling plant in the region. “Both parties are working with great commitment to drive the process forward and the ambition to commence the project during this year remain to the highest extent”, says Thomas Sörensson. Vanlead has a large number of subsidiaries, one of them being tyre manufacturer South China Tire & Rubber Co, the first large-scale state-owned enterprise to introduce professional technology to produce full-series radial tires in China. One of South China Tire & Rubber’s brands is Wanli Tire which, with annual capacity of 16 million tires and 2,100 employees, is the largest radial tire manufacturer in Southern China and one of the largest radial tire exporters in the country. Vanlead Group’s tyre production represents a strategic area both domestically and internationally. The company is one of the world’s largest tyre manufacturers and exports tyres to Europe, the United States, and other parts of the world. Their aim is to expand production capacity, improve economy of scale, enhance competitiveness and become a domestic leading and world-famous rubber and tyre enterprise. “China is the world’s biggest tyre market and new solutions for processing end-of-service tyres more circularly are necessary from both environmental and resource-related perspectives. Vanlead wants to take the initiative in the industry,” says Thomas Sörensson. Vanlead Group recently signed a Project Investment letter of intent with the state of South Carolina to start building a $1 billion plant in South Carolina next year. The group also plans to set up a research centre in Europe and a joint research facility in Akron, Ohio. The US tyre plant will mark a major step in Vanlead's effort to build its brand globally. Environmental efficiency Vanlead's new Hefei factory, featuring so-called Industry 4.0, has been and is set up to be one of the world’s most automated tyre production units. To make the production greener, the factory has power generating facilities using steam pressure differential installed, saving close to $800,000 annually in energy costs. The factory’s water recycling system also enables the factory to achieve zero wastewater discharge. “Vanlead share Enviro’s view that our unique production technology for sustainable materials is the future for the tyre industry. The fact that a state-owned company is the first to exhibit this high level of ambition is very positive,” says Thomas Sörensson. Read more about Vanlead Group  For further information, please contact:Thomas Sörensson, CEO Enviro, tel: +46 (0)735-10 53 43, thomas.sorensson@envirosystems.se  Stig-Arne Blom, Board Chairman Enviro, tel: +46 (0)705-25 16 15, stigarne@blom.pp.se Scandinavian Enviro Systems ABRegnbågsgatan 8CSE-417 55 Gothenburginfo@envirosystems.sewww.envirosystems.se

Saab receives Self-Protection Systems order for H225M Caracal helicopters

Saab’s Integrated Defensive Aids Suite (IDAS) protects the crew by enhancing platform survivability in sophisticated, diverse and dense threat environments. The system provides timely warning against radar, laser and infrared (IR) guided threats and automatically deploys the appropriate countermeasures. “This order confirms Saab´s strong position as a supplier of world class airborne self-protection systems, which improves the customer’s operational capabilities,” says Anders Carp, head of Saab business area Surveillance. Production of the IDAS self-protection system will take place in 2017- 2018 at Saab Grintek Defence premises in Centurion, South Africa, with deliveries scheduled for 2020. “Saab has a longstanding relationship with Airbus and the order of our effective and reliable IDAS system reaffirms our partnership,” says Trevor Raman, CEO of Saab Grintek Defence. The system has a long and successful history with proven capability on many airborne platforms such as the Saab 2000, Agusta-Westland A109, Super Lynx 300, Boeing CH-47 Chinook, Denel Rooivalk and Oryx, Eurocopter Cougar, Puma and Super Puma, NH Industries NH90, C-130 and L100 Hercules, Sukhoi Su-30MKM. Deliveries are ongoing for the HAL Advanced Light Helicopter Dhruv. For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Asetek announces new data center order to cool NVIDIA’s P100 GPU accelerators

Aalborg, Denmark, 23 June 2017 – Asetek today announced a new order from Penguin Computing, Asetek’s longstanding OEM partner for a new undisclosed HPC (High Performance Computing) installation.  Asetek’s proprietary Direct-to-Chip (D2C) liquid cooling technology was selected by Penguin Computing to cool NVIDIA’s P100 GPU accelerators, the most advanced GPUs yet produced by NVIDIA.  “Utilizing Penguin's Tundra ES platform with Asetek's D2C liquid cooling technology will allow our government clients to push the boundaries of these GPU's for deep learning research,” said Ken Gudenrath, Director, Federal Division, Penguin Computing. “Asetek has been chosen to cool the world’s most advanced GPUs. It is an important validation of our offering and we are pleased that our OEM partner, Penguin Computing, continues to select Asetek technology. This is an initial order, and we expect additional deliveries to follow,” said André Sloth Eriksen, CEO and founder of Asetek. Asetek signed a global purchasing agreement  with Penguin Computing in 2015. This initial order is for 140 loops to be used with Asetek’s RackCDU Direct-to-Chip (D2C) liquid cooling solution and have a value of USD 40,000 with delivery in August 2017. About AsetekAsetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK). For more information, visit www.asetek.com For further information, please contact:André S. Eriksen, Chief Executive OfficerMobile: +45 2125 7076, e-mail: ceo@asetek.com

Investigation by the Brazilian Administrative Council for Economic Defense comprises two Getinge entities

Two of Getinge’s entities in Brazil, Maquet Cardiopulmonary do Brasil Indústria e Comércio Ltda and Maquet do Brasil Equipamentos Médicos Ltda, and employees within these companies are being investigated by the Brazilian General Superintendence of the Administrative Council for Economic Defense (CADE) regarding alleged cartel activities. The investigation is part of ongoing public investigations on cartel activities related to the sales of medical equipment and is being carried out by the Brazilian authorities. According to a press release issued by CADE, 46 companies, 80 individuals and the industry association Associação Brasileira de Importadores e Distribuidores de Implantes (ABRAIDI) are under investigation. Potential consequences for Getinge are not yet known and too early to comment upon. Media contacts: Jeanette Hedén Carlsson,EVP Communications & Brand ManagementPhone: +46 (0)10 335 1003Email: jeanette.hedencarlsson@getinge.com Anna Appelqvist,Head of Media RelationsPhone: +46 (0)10 335 5906Email: anna.appelqvist@getinge.com This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CEST on June 24, 2017. About GetingeGetinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our firsthand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people - today and tomorrow.  

EQT VII to invest in global “hidden champion” and medical mobility technology market leader Ottobock

· EQT VII to acquire a 20% stake in Germany-based Ottobock, the global market leader in medical mobility solutions ranging from prosthetic and orthotic products to wheelchairs and accompanying services · Founded by Otto Bock in 1919, the Company has been an industry innovator and has launched the first completely microprocessor-controlled lower limb prosthesis, among others · EQT will support majority owner Professor Hans Georg Näder and the management team on Ottobock’s continued growth trajectory and focus on innovation The EQT VII Fund (“EQT VII”) has entered in to an agreement to acquire a 20% stake in Ottobock (or “the Company”) from Otto Bock HealthCare GmbH. Since its foundation in 1919 by Otto Bock, the Company has been a synonym for revolutionizing, innovating and moving forward medical mobility technology. Otto Bock started the first serial production of prosthetic components post World War I. After World War II, the Company introduced the modular solution for upper and lower limb prosthesis. In 1997, Ottobock launched the C-Leg, the world's first completely microprocessor-controlled lower limb prosthesis solution. Over nearly a century, Ottobock’s products have allowed users to achieve a better quality of life, more mobility and independence. True to this philosophy, Ottobock has actively supported the Paralympic Games since 1988 and has been a partner of the International Paralympic Committee since 2005. Ottobock is headquartered in Duderstadt, Germany and operates subsidiaries in more than 50 countries with more than 7,000 employees worldwide. In 2016, the Company generated more than EUR 880 million in sales and EQT valued the Company at EUR 3.15 billion. “I am very pleased to take EQT on board as a partner who shares the values of a family-backed company given its Wallenberg background. EQT also has a track record of sustainable value creation and growth”, says Professor Hans Georg Näder, majority shareholder and grandson of the company founder. “I am convinced that EQT’s experience in developing companies will allow us to continue Ottobock’s success story well beyond the Company’s 100th birthday”, concludes Professor Näder. “We are impressed by Ottobock’s long heritage of innovation and its ability to define the landscape of mobility solutions in the area of wearable home rehabilitation regarding the growing market of human bionics. Based on EQT’s deep healthcare expertise, and as one of the most active investors in the sector, we will be a strategic partner to Professor Näder, the management and the Company. We look forward to working together and contributing to the continued success of Ottobock”, added Marcus Brennecke, Partner at EQT Partners and Investment Advisor to EQT VII. The transaction is subject to approval by the relevant competition authorities and is expected to close in the second half of 2017. Contacts: Marcus Brennecke, Partner at EQT Partners, Investment Advisor to EQT VII, +49 89 255499 20 EQT Press office, +46 8 506 55 334 About EQT EQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About Ottobock Ottobock develops medical technology products and fitting concepts for people with limited mobility in the fields of Prosthetics, Orthotics, Human Mobility (wheelchairs, rehabilitation devices) and MedicalCare. Subsidiaries in over 50 countries offer quality “Made in Germany” worldwide and employ more than 7,000 people. Ottobock has been a family-managed company since its founding in 1919 and has also been supporting the Paralympic Games with its technical know-how since 1988. More info: www.ottobock.com  

Cleantech Invest portfolio firm Nuuka Solutions Lands in California

Cleantech Invest portfolio company Nuuka Solutions has established a subsidiary company in Los Angeles, CA. The Californian subsidiary will be a joint effort between Nuuka and Ms. Marylou Garcia who will be spearheading the efforts to bring yet another Nordic technology to American shores. Cleantech Invest owns 34% of Nuuka. Nuuka, who will own 51% of the Joint Venture, is a data software and platform company operating in the rapidly developing smart building sector. They have realized significant growth in the first two quarters of 2017 and are poised to continue this growth into the second half of the year. California is leading the United states in Cleantech adoption, and businesses such as Nuuka continue to see the greater Los Angeles area as one of the key markets to tackle if they want to become a leading player in the cleantech movement. Nuuka is doing their part by making smarter and sustainable buildings a reality in the United States. Marylou Garcia, CEO and President of Nuuka Inc., has an MBA from Wharton and is well established in the California market. She is also the Managing Director for Expense Reduction Analysts, Los Angeles – an enterprise that helps organizations put additional cash flow to work by further lowering supplier costs, without any compromise to quality and service. Through partners and alliances, Nuuka Inc will be able to reach thousands of potentials customers in the United States. Nuuka CEO, Mikko Valtonen: “We have had a very busy first 2 quarters of 2017. We have been successful in getting key new customers to use our software both here in the Nordics, and abroad in Benelux and the US. We see the opening of a subsidiary in California as a logical next step on our growth journey to becoming one of the key players in this rapidly developing smart building market. We are very excited about the partnership we now have with Marylou Garcia and her extensive networks. We look forward to starting projects in California in the very near future” Cleantech Invest Chairman of the Board, Lassi Noponen based in Los Angeles: “Cleantech Invest combines the best Nordic cleantech with formidable American entrepreneurship by bringing a set of its portfolio companies to the US and Nuuka is first project to go live. We have several other projects in progress and hope to be able to announce the next company very soon. Nordic Cleantech is very competitive on the global stage, as Finland and Sweden continue to act as the epicenter for technological innovation. There is tremendous market potential to bring these technologies to the US.” Consul General of Finland in Los Angeles, Stefan Lindström: “California and the Nordics are leaders in clean technologies. We are here to support Finnish companies’ entry to the massive US market and have been happy to contribute to Cleantech Invest’s and progress in California. Innovators like Nuuka are important pioneers and will pave way for many more Nordic cleantech companies’ emergence to the US market.” Cleantech Invest CEO, Alexander Lidgren: “We set up our office in California to help our companies grow in the USA. I don’t think Lassi could have found a better partner for Nuuka than Marylou Garcia. Nuuka has a scalable solution that real estate owners in the Nordics love, and I am really exited to see how it will be received in the American market.” Marylou Garcia, CEO and President of Nuuka Inc: “As buildings continue to get smarter and generate massive amounts of data, Nuuka provides a cost efficient solution to allow property owners, developers and managers real-time, instantaneous visibility to all their automation systems for quick decision and action. Nuuka combines sustainability, energy efficiency and customer satisfaction under one platform. California has historically been first to adopt and commercialize new technologies, and I am looking forward to begin working with Nuuka solutions in continuing to make that statement true.”

BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA® for Advanced Lung Cancer

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are delighted to have received this grant award, the largest grant from the “Industrial Development” program ever made by Innovasjon Norge. BGB324 is a novel small molecule Axl inhibitor that, as a one-a-day pill, offers an exciting opportunity to treat multiple cancers through a potentially universal mechanism. Axl signalling is a central process that promotes cancer cells to become aggressive. By blocking Axl signalling, tumour cells revert to a stable state where we believe they can be targeted and destroyed by the immune system and re-sensitized to other cancer therapies. We believe therefore that BGB324 alone and in combination with immunotherapies, such as KEYTRUDA, has the potential to significantly improve the clinical outcomes in a broad range of cancers. We anticipate announcing the results of this combination Phase II study in 2018.” The grant from Innovasjon Norge is an Industrial Development Award (IFU). The IFU program is directed to Norwegian companies developing new products or services in collaboration with foreign companies. The NOK 24 million grant will contribute towards BerGenBio’s costs of running this specific Phase II clinical trial. Director Nina Broch Mathisen of Innovasjon Norge, said: ”We are pleased to have made this very significant grant award to BerGenBio. We have been very impressed by the innovation demonstrated by BerGenBio in a highly competitive global market, in an industry within our defined area of focus. The clinical data that has already been generated with BGB324, has convinced us to support the Phase II study in advanced lung cancer patients assessing BGB324 in combination with KEYTRUDA. We are optimistic that this study will contribute to value creation in Norway, positively promote the Norwegian healthcare sector, and will offer renewed hope to a large number of cancer patients.”  In March 2017, BerGenBio entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), focused on the clinical evaluation of BGB324 with KEYTRUDA® in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). About BerGenBio ASA BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of Axl kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers. BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in Phase II clinical development in four major cancer indications. It is the only selective Axl inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS). In advanced non-small-cell lung cancer (NSCLC), BGB324 is tested in combination with TARCEVA® (erlotinib) as well as TAXOTERE® (docetaxel) and KEYTRUDA® (pembrolizumab). In advanced melanoma, combination of BGB324 with either MEKINIST® (trametinib) and TAFINLAR® (dabrafenib) or KEYTRUDA® are being explored. A further combination of BGB324 with KEYTRUDA® is being tested in triple negative breast cancer (TNBC). The clinical trials combining BGB324 with KEYTRUDA® in NSCLC and TBNC are conducted in collaboration with Merck & Co. Inc. (MSD). The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149 an anti-Axl monoclonal antibody. For further information, please visit: www.bergenbio.com KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech.  -Ends- Contacts   Richard Godfrey  CEO, BerGenBio ASA +47 917 86 304 David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Lifco acquires Perfect Ceramic Dental in China

Lifco has signed an agreement to acquire the Chinese dental company Perfect Ceramic Dental (PCD). PCD is a dental laboratory that produces dentures and dental prosthetics mainly for MDH, a German Lifco subsidiary. PCD has since the 1990s produced dental crowns, bridges and complex restorations for MDH Germany. The company has its main facility in Shenzhen, China. PCD reported net sales of 118 MHKD in 2016. Approximately 80% of PCD’s sales is generated by MDH, a Lifco subsidiary in Germany, which means that the acquisition will have very limited effect on Lifco’s consolidated external sales. PCD currently has about 850 employees. The acquisition will not have any significant effect on Lifco’s earnings or financial position in current financial year. For more information please contact: Per Waldemarson Head of Business Area Dental Phone +46 70 840 00 63, E-mail per.waldemarson@lifco.se Åse Lindskog  Media and investor relations managerPhone +46 730 244 872, E-mail ir@lifco.se About Lifco Lifco acquires and develops market-leading niched operations with the potential to deliver sustainable profit growth and strong cash flows. The Group has three business areas: Dental, Demolition & Tools and Systems Solutions. Lifco has a clear corporate philosophy which implies a long-term perspective, focus on profits and a highly decentralized organization. Lifco has 133 companies in 26 countries. In 2016, the Group’s net sales amounted to SEK 9 billion and the EBITA margin was 15%. For more information, visit www.lifco.se.

DIGNITANA MEDICAL ADVISORS HELP LAUNCH INTERNATIONAL SCALP COOLING COLLABORATION AMONG TOP CANCER CENTERS WORLDWIDE

Lund, Sweden – June 26, 2017 – Dignitana AB, a world leader in medical scalp-cooling technology and manufacturer of the DigniCap® scalp cooling system, is partnering with the organization known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, which was launched this past weekend at the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer (MASCC),  held in Washington, D.C. Led by six globally-recognized experts in cancer care, CHILL is an initiative designed to collect and track evidence-based patient information and provide clinical guidance for health practitioners and patients using scalp cooling medical devices that reduce hair loss for patients receiving chemotherapeutic cancer treatments. Data collected through the initiative will help establish industry-standard best practices and ensure maximum effectiveness of these treatments worldwide. A new website, scalpcooling.org , will serve as a global hub for patients and care providers seeking information about hair loss and scalp cooling technology, as well as a decision aid with data from the CHILL registry showing chances of hair loss with and without scalp cooling. With an estimated 14.1 million patients diagnosed with cancer worldwide in 2012 (according to World Cancer Research Fund International ), cancer is a significant global health issue affecting every region and socioeconomic group. The CHILL Registry strives to become a platform that allows clinicians to understand cancer-related hair loss during leading edge cancer therapies, improve supportive care by comparing their own data with international estimates, and access the extensive resources of comprehensive cancer treatment teams around the world. “At Dignitana, we take pride in our ability to be a leader of innovation and remain on the cutting edge of technological developments that help us provide the best possible care and outcomes for our patients,” said Johan Ericsson, Chief Executive Officer of Dignitana AB. “The CHILL Registry is an incredible platform that will allow us to track progress and connect with physicians around the world to ensure that we can continue to deliver the most effective scalp cooling treatments available.” “Scalp cooling is well-recognized around the globe as a therapeutic solution to one of the most troublesome side effects of chemotherapy,” said CHILL Executive Board Member Dr. Corina van den Hurk, Netherlands Comprehensive Cancer Organisation.  “The launch of the CHILL Registry is a significant step forward as we work together to develop best practices in supportive care.” CHILL has designed an online registry that makes communication and global research accessible to all health care professionals interested in using scalp cooling with their chemotherapy patients. The registry collects data about severity of hair loss of patients with and without scalp cooling. For patients undergoing treatment with scalp cooling, physicians can also gather information on tolerance and satisfaction with the results of treatment. As scalp cooling results vary depending on several factors, the CHILL Registry amasses information including:   · Clinical: type and dose of chemotherapy, infusion time, post-infusion cooling time · Patient characteristics: age, ethnic background, hair thickness, chemical treatment of hair, smoking, body mass index · Efficacy: severity and pattern of hair loss, and in case of scalp cooling: tolerance and satisfaction · Follow up information: dependent on availability and willingness of patient to be contacted six months after treatment to evaluate hair growth and results to determine incidence of persistence hair loss Launching this unique initiative at the Multinational Association of Supportive Care in Cancer (MASCC) conference  June 22-24, 2017 in Washington, DC, the clinicians spearheading the CHILL registry and serving as the CHILL Executive Board include: · Corina van den Hurk, PhD  , Epidemiologist, Netherlands Comprehensive Cancer Organisation (IKNL) – Netherlands · Annie Young, PhD , Professor of Nursing, University of Warwick and University Hospital Coventry and Warwickshire NHS Trust – Coventry, United Kingdom · Frances Boyle, AM , MBBS (Hons 1), PhD Pharmacology, FRACP (Medical Oncology), Professor of Medical Oncology and Director of Patricia Richie Center for Cancer Care and Research, Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital and University of Sydney – Sydney, Australia  · Hope Rugo, MD , Professor of Medicine and Director, Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center – San Francisco, California, United States · Mario Lacouture, MD , Director, Oncodermatology Program, Memorial Sloan Kettering Cancer Center – New York, New York, United States · Julie Winstanley, PhD, MSc, CStat, CSci and Associate Professor, Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital and University of Sydney – Sydney, Australia   “Hair loss associated with chemotherapy can be devastating for many women,” said oncologist Hope S. Rugo, MD, Professor of Medicine, Director, Breast Oncology and Clinical Trials Education at UC San Francisco and a breast cancer specialist with the UCSF Helen Diller Family Comprehensive Cancer Center. “Working with Dignitana to clinically test and introduce the first FDA-cleared scalp cooling medical device to the U.S. market, our aim has been to care for the emotional wellbeing of our patients as we aggressively treat their cancer. The clinician-led CHILL registry is a forward-looking commitment to providing patients with the best possible practice insights and innovations as scalp-cooling technology continues to advance and evolve.” Positive results from two separate multi-center clinical trials on scalp cooling were published in February 2017 by The Journal of the American Medical Association (JAMA). Both U. S. studies of breast cancer patients using the DigniCap  and Paxman  scalp cooling devices found that a majority of patients achieved favorable results from scalp cooling treatments to prevent hair loss. The scalp cooling medical device features a tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. Once the cap is fitted to the head, the temperature of the scalp skin is significantly lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp skin, as well as reduced cellular uptake of drugs due to decreased intra-follicular metabolic rate. These factors together minimize the hair loss that is a side effect of many chemotherapy agents.  THE CHILL Registry is funded by Dignitana , maker of The DigniCap® Scalp Cooling System and Paxman, maker of the Paxman Scalp Cooling System.

CEO to leave Dustin

The search process for his successor will be initiated immediately. Georgi Ganev will remain as CEO during his six-months notice period.   - Georgi Ganev has built a strong team and developed Dustin’s business through geographical expansion and a broadened offering during his five years as CEO. Thanks to a strong position and an efficient business model Dustin is well positioned for future growth. On behalf of the whole board I want to give my warmest thanks to Georgi for his great efforts for Dustin and wish him all the best in his future role, said Fredrik Cappelen, Chairman of the Board of Directors Dustin. - It has not been an easy decision to leave Dustin. I am very proud of what we have achieved together and is confident that the team at Dustin will continue to successfully develop the company, said Georgi Ganev CEO of Dustin. Georgi Ganev has been the CEO of Dustin since 2012. Contact person: Eva Ernfors, Head of Information eva.ernfors@dustin.se, +46 70 258 62 94 This information is information that Dustin Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on June 26, 2017. About Dustin Dustin is one of the leading Nordic resellers of IT products with associated services to companies, the public sector and private individuals. With its core business in e-commerce, Dustin functions as a bridge between the manufacturer’s wide-ranging offerings and customer requirements, in which Dustin’s employees support customers in finding the appropriate solution for them. Dustin is a one-stop-shop that offers some 200,000 products with associated services, features and solutions. Operations are conducted in Sweden, Denmark, Norway and Finland. The company has approximately 900 employees. Sales during the 2015/16 financial year amounted to approximately SEK 8.3 billion. About 90 per cent of Dustin’s income derives from the corporate market with a focus on small and medium-sized companies. Dustin Group has been listed on Nasdaq Stockholm since 2015 and has its head office in Nacka, Stockholm.

Carina Strand appointed Head of Group HR at Swedbank

Carina Strand is currently Head of HR at IBM Sweden, where she is also part of the Management Team. -Carina has a solid background within the HR area, and the right tools to support Swedbank's journey towards a modern and digital bank while increasing both employee satisfaction and pride. Carina's broad experience will be a very valuable asset in the Group Executive Committee and for all our 14,000 employees, says Birgitte Bonnesen, President and CEO of Swedbank. Carina Strand has held a couple of different HR positions within IBM during the last decade. -I really look forward to joining Swedbank. With its strong culture and values, and large customer base throughout Sweden and the Baltics, Swedbank has a unique position of capturing the opportunities of the digital transformation, which will create great benefits for both customers and employees, says Carina Strand, future Head of Group HR of Swedbank. Carina Strand will take on her new role on 1 October 2017. For further information:Josefine Uppling, Group Press Officer, Swedbank, +46 76 114 54 21 This announcement involves the disclosure of inside informationSwedbank AB (publ) is required to disclose this information pursuant to Regulation (EU) No 596/2014 on market abuse, the Swedish Securities Markets Act (2007:528), the Swedish Financial Instruments Trading Act (1991:980) and the regulatory framework of Nasdaq Stockholm. This information was sent to be published on 26 June 2017 at 8 am CET.

Cantargia: Preclinical studies of IL1RAP and CAN04 in solid tumours presented at EACR-AACR-SIC in Florence

Cantargia is developing the humanised antibody CAN04, against the target molecule Interleukin-1 Receptor Associated Protein (“IL1RAP”), for treatment of cancer. Cantargia has previously shown that antibodies targeted at IL1RAP can block IL-1 signalling and stimulate the killing of cancer cells in various preclinical cancer models. The data that was presented shows that IL1RAP is expressed in several cell lines from triple negative breast cancer and non-small cell lung cancer. CAN04 blocks the release of the tumorigenic molecules IL-6 and IL-8. CAN04 can also stimulate the immune system’s NK cells to kill these cell lines. The studies were conducted by Dr Ramin Massoumi’s team at Lund University and the results were presented as a poster by Dr Wondossen Sime. “Presentations of our CAN04 antibody at international scientific conferences are important for Cantargia”, CEO Göran Forsberg says. “This data highlights the potential of CAN04. In addition to our focus on non-small cell lung cancer and pancreatic cancer, triple negative breast cancer could be an important future disease in the context of CAN04 development”. For further information, please contact Göran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 26 June 2017, at 8.30am. About Cantargia  Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.  Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

Itiviti delivers multi-protocol automated testing for CSE System

To deliver the solution, CSE deployed VeriFIX by Itiviti, the industry standard in automated testing, with multiple FIX protocol versions as well as proprietary binary protocols in order to implement full regression testing of order entry, market data feeds, and regulatory requirements for the CSE Trading System. This full regression testing suite facilitates validation of complete trading workflows across all protocols and interfaces. “Itiviti has enabled CSE to regression test our platform and receive automation quality benefits both of which has added operational efficiencies to our release cycles” said David Timpany, Vice President, Technology & Operations for CSE. “Our regression testing time frame has been reduced from multiple people for four weeks to an overnight automated test run with defect report generation. With next day feedback to our development team, we have dramatically decreased the defect turnaround timeframe. These improvements will help us to continue offering our clients a competitive advantage in the marketplace.” Multi-protocol technologies are a top priority at Itiviti. Itiviti’s solutions support both industry standard and proprietary protocols and are available for firms looking to redesign or scale-up their trading technology for future client demand. “We are pleased to continue to partner with CSE to accelerate deployment of CSE’s Trading System and help achieve cost and system efficiencies,” said Jesper Alfredsson, President Americas, Itiviti. “Our work with CSE is another example of how Itiviti can help achieve test automation for FIX and proprietary protocols.” Firms that invest in multi-protocol technologies will be the leaders in offering high quality, reliable market access for a broader range of market participants. About ItivitiItiviti is a world-leading technology provider for the capital markets industry. Trading firms, banks, brokers and institutional clients rely on Itiviti technology, solutions and expertise for streamlining daily operations, while gaining a sustainable competitive edge in global markets. With 13 offices and serving more than 400 customers worldwide, Itiviti was formed by uniting Orc Group, a leader in trading and electronic execution, and CameronTec Group, the global standard in financial messaging infrastructure and connectivity. From its foundation in 2016, Itiviti has a staff of 400 and an estimated annual revenue of SEK 700 million. Itiviti is committed to continuous innovation to deliver trading infrastructure built for today’s dynamic markets, offering highly adaptable platforms and solutions, enabling clients to stay ahead of competitive and regulatory challenges. Itiviti is owned by Nordic Capital Fund VII. About CSECSE, The Exchange for Entrepreneurs®, is home to more than 300 listed companies covering a broad range of industry sectors. CSE provides trade execution, smart routing, risk management, compliance and market information services for Canadian listed securities across multiple markets.   Recognized as an exchange by the Ontario Securities Commission in 2004, the CSE is designed to facilitate the capital formation process for public companies through a streamlined approach to company regulation that emphasizes disclosure and the provision of efficient secondary market trading services for investors.  For further information, please contact: Itiviti Jesper Alfredsson, President Americas, Itiviti, Tel: +1 312 541 4500, jesper.alfredsson@itiviti.comMegan Geldman, Senior Marketing Manager Americas, Itiviti, Tel: +1 312 541 4181, megan.geldman@itiviti.com www.itiviti.com Follow Itiviti on social media on Twitter @Itiviti_AB , on Facebook @ItivitiAB , and on LinkedIn   CSE David Timpany, Vice President, Technology & Operations, CSE, Tel: 416-367-7355, david.timpany@thecse.com  www.thecse.com; CSE blog at http://blog.thecse.com  Follow the CSE on social media on Twitter @CSE_News  and on Instagram and Facebook @CanadianSecuritiesExchange 

Ericsson demonstrates innovations at Mobile World Congress Shanghai

From June 28 to 30, Ericsson (NASDAQ: ERIC) will share successful customer case studies and demonstrate the latest innovations in 5G, IT and Cloud, and the IoT to customers, partners and media at Mobile World Congress Shanghai. Highlights on display at the Ericsson booth will include the latest 3.5GHz 5G radio, Big Data Analytics, and the IoT Accelerator  platform. Ericsson will participate in a full schedule of activities during the week of the event, under the theme “Making 5G real, partnership with Ericsson”, including: · June 27 – Ericsson will host a Unified Delivery Network conference with participants such as Asian operators and content providers. On the same day, Ericsson will make a joint announcement with China Telecom · June 28 – Ericsson, China Unicom and Qualcomm will make a joint announcement during a media conference at the Ericsson booth. Chris Houghton, Head of Market Area North East Asia at Ericsson, and Shao Guanglu, Executive Director and Senior Vice President of China Unicom, will address the media. Later that day, Ericsson Senior Vice President and Head of Business Area Digital Services Ulf Ewaldsson will make a keynote speech at the GTI Summit · June 29 – Ewaldsson will participate in a panel session at the Network Evolution Summit · June 30 – George Guo, Head of IT & Cloud, Market Area North East Asia, Ericsson will make a keynote speech at the Enterprise & The Cloud Summit Chris Houghton, Head of Market Area North East Asia at Ericsson, says: “At Mobile World Congress Shanghai, Ericsson will demonstrate how breakthroughs in 5G, IT and Cloud, and the IoT are revolutionizing industries. By redefining what’s possible with radio systems and federated network slicing, software-defined networking and network functions virtualization, and NarrowBand IoT, we’re pioneering a wide range of transformative solutions.” Ericsson at Mobile World Congress Shanghai 2017 Everything moves fast on the journey toward the Networked Society, and breakthroughs such as autonomous driving, remote surgery and immersive virtual reality are rapidly transforming industries of all kinds. Everywhere we look, companies are breaking out of their traditional comfort zones to adopt innovative and disruptive business models. Ericsson, the driving force behind 5G and the IoT, is a willing partner in the ongoing digital revolution. From June 28 to June 30, Ericsson is demonstrating cutting-edge technologies, innovative solutions and a wide range of customer success stories at Mobile World Congress Shanghai. Join us in Booth A61, Hall W4 at the Shanghai New International Exhibition Center (SNIEC) or engage with us online. See you there! NOTES TO EDITORS For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericsson www.youtube.com/ericsson MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

Transcom appoints new CEO and becomes sister company with Xzakt following an acquisition by Altor

Stockholm, 26 June 2017 Michael Weinreich has been appointed new CEO of Transcom WorldWide (Transcom), replacing Johan Eriksson. Michael was previously CEO of Arvato Financial Services, but has recently also been a VC Partner at FinLeap. Michael will join Transcom on September 1. Michael has a comprehensive industry experience from hands-on call center operation management to sophisticated international business process outsourcing for collection and payment services. He is very much up-to-date in modern digital solutions due to his role as VC Partner and angel investor. “After several successful years as President & CEO of Transcom, Johan Eriksson recently informed the Board of his intention to leave his position. I would like to extend my gratitude for Johan Eriksson’s commitment and contribution in developing Transcom. I am also very grateful that Johan has promised to stay on to make the transition smooth. Michael has a great track-record from this industry and has exceptional international experience – which makes him perfect as the successor for the CEO role in Transcom” says Fredrik Cappelen, Chairman of Transcom. In parallel with the appointment of a new CEO, Transcom’s owner Altor Fund IV (Altor) has via a holding company acquired the Swedish customer care company Xzakt kundrelation (Xzakt) from the founder and owner Gunilla von Platen. Transcom and Xzakt will be structured as sister companies. The two brands will be run independently. Gunilla and Alfred von Platen will become minority owners in the holding company and partner with Altor in developing both Xzakt and Transcom. “I believe our new Group can build something exciting in this industry. Xzakt has created an unprecedented profitable growth-saga in the customer contact business. Now we will embrace the global footprint from Transcom and I believe we are just in the beginning of a wonderful journey together”, says Gunilla von Platen, founder of Xzakt. For further information, please contact: Stefan Pettersson, Head of Group Communications Telephone +46 70 776 80 88

Nurminen Logistics Plc will publish prospectus regarding the Rights Offering, Capitalization and indebtedness and working capital statement

Nurminen Logistics Plc                                             Stock Exchange Release              26 June 2017 at 1:55 P.M. Finnish TimeThe Finnish Financial Supervisory Authority has today approved the Finnish language version of the prospectus regarding to the rights offering of maximum of 29 229 764 new shares of Nurminen Logistics ("Nurminen Logistics"). The Finnish listing prospectus will be available on Nurminen Logistic’s Finnish website at www.nurminenlogistics.fi as of 26 June 2017. The terms and conditions of the Rights Offering were published in a separate stock exchange release on 26 June 2017. The following table sets out the Company’s capitalisation and indebtedness as at 30 April 2017. The figures are unaudited and they are based on the Company’s group-internal monthly reports regarding the Company’s capitalisation and indebtedness as at 30 April 2017. The table is to be read in conjunction with the audited consolidated financial statements for the financial years ending 31 December 2016 and 31 December 2015 included in Appendix A of the Prospectus. No significant changes have taken place in the Company’s capitalisation and indebtedness since 30 April 2017. 30 April 2017MEUR  (unaudited) Current interest-bearing debt Secured  2 Total  2  Non-current interest-bearingdebt Secured   22 Total  22  Total interest-bearing debt  24  Shareholders’ equity belonging tothe owners of the parent company Share capital  4 Hedge reserve Contingency reserve Hybrid bond Other reserves  21 Translation differences  -7 Retained earnings   -13 Total shareholders’ equity  6  Total shareholders’ equity and 30 interest-bearing debt  Net indebtedness MEUR Liquidity (A) Cash and cash equivalents  4 Total  4  Current interest-bearing debt(B) Financial debt  2 Total  2  Net current indebtedness (C = -2 B–A)  Non-current interest-bearing debt(D) Financial debt   22 Total  22  Net indebtedness (C+D)  21  Working Capital Statement The Company’s current working capital is not, as at the date of this Prospectus, sufficient to cover its needs in the next 12 months. If the Company’s cash flow develops in the manner predicted and planned by the Company, the working capital will, as at the date of the Prospectus, be sufficient for the Company’s operative needs for the next 12 months, but the cash flow will not, according to the Company’s management, be sufficient to pay the obligations subject to security limits related to the customs bonds received by the Company from the financial institutions. The securities related to the customs bonds are, in the opinion of the Company’s management, customary in the forwarding business. The Company has customs securities related to the customs bonds from financial institutions, and the covenant terms included therein impose conditions, for instance, regarding the Company’s equity ratio (the total amount of the security limits received from the financial institutions stands approximately at EUR 8.9 million, of which amount, a share of approximately EUR 7.5 million is subject to covenant terms) (see section “Information about Nurminen Logistics—Significant Agreements—Financing Agreements”). The covenant terms had been breached on 31 December 2016, but the Company has received an undertaking from the financiers until 31 December 2017 pursuant to which no sanctions will be imposed on the Company as a result of a breach of the covenant terms. In the opinion of the Company’s management, the covenant terms of the financing agreement would not be met by 31 December 2017, upon the occurrence of which, the obligations subject to the customs security would immediately fall due for payment. It is also not certain whether the Company is able to operate in the future in such a way that the covenant and other terms included in its financing agreements would not be breached and whether the Company’s financiers would be willing, in connection with possible breaches, to re-negotiate the terms of financing or security without requiring the expedited or immediate payment of the loans or release of the security. Provided that the Rights Offering is subscribed in full and the Convertible Hybrid Bond is executed, the Company will, according to its management, be in a position to meet the financiers’ covenant terms related to the customs securities. (See section “Background and Reasons for the Rights Offering and the Use of Proceeds”.) According to the Company’s management, the Directed Conversion Issue and the Convertible Hybrid Bond, in respect of which the Company has received subscription undertakings from Ilmarinen in the manner provided for in certain terms and conditions and the subscription of which will reduce the amount of the Company’s debt (by approximately EUR 2.4 million in the case of the Directed Conversion Issue and by approximately EUR 1.5 million in the case of the Convertible Hybrid Bond), make it possible for the Company to meet the covenant terms of the security limits granted by the financing banks. Provided that the Company meets the financing banks’ covenant terms in the manner described above, the customs security agreed upon by the Company with the financing banks would be in force until 30 June 2018. The Company and the financing banks have negotiated, at regular intervals, on the customs securities, and it is the Company’s intention to have an agreement on the customs securities with the financing banks even after 30 June 2018. Should the Company not be successful in agreeing with the financing banks on the customs securities after 30 June 2018, the Company shall take steps to have the resulting need for additional financing covered. According to the Company’s management, the steps required to cover the need for additional financing could include (i) the reorganisation of the financing and securities, (ii) the sale of the Company’s operations and assets, and (iii) combinations of the above-mentioned means. Should the Rights Issue and the Convertible Hybrid Bond not be executed and should the Company’s assets not be sufficient for the payment of the customs security obligations in a situation in which the covenant terms of the security limits had not been met, the need for financing shall be covered by means of additional financing and by resorting to other measures. The Company’s management has assessed the measures required to be taken in the case of possible additional financing, including (i) the reorganisation of the financing and securities, (ii) the sale of the Company’s operations and assets, and (iii) combinations of the above-mentioned means. Nurminen Logistics PlcBoard of Directors Additional information: Olli Pohjanvirta, Chairman of the Board of Directors, telephone +358 40 900 6977Marko Tuunainen, President and CEO, telephone +358 10 545 7011 Distribution: Nasdaq Helsinki OyKeskeiset tiedotusvälineetwwww.nurminenlogistics.fi IMPORTANT INFORMATION The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa or any other country where such publication or distribution would violate applicable regulation or would require any measure to be undertaken, in addition to the requirements under Finnish law. The issue, exercise or sales of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. The information contained herein shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published by the Company. This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia). This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, unless registered under the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act and in compliance with any applicable state securities laws of the United States. There is no intention to offer securities in the United States. The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland and which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression an “offer of securities to the public” means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to exercise, purchase or subscribe the securities, as the same may be varied by any measure implementing the Prospectus Directive in that Relevant Member State and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU. This announcement does not constitute an offer of securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This announcement and the offer when made are only addressed to and directed at persons who (1) are outside the United Kingdom, (2) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000, Order 2005 as amended (the “Order”) or are persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies, unincorporated associations, etc”) or (3) to persons to whom an invitation or inducement within the meaning of section 21 of the Financial Services and Markets Act 2000 may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The information set out in this announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

Swedish digital forensics company Bitsec AB joins forces with Nixu to form even stronger European cybersecurity services company

Nixu CorporationPress release on 26.6.2017 at 14:15 EET      Swedish digital forensics company Bitsec AB joins forces with Nixu to form even stronger European cybersecurity services companyNixu has now one of the largest cybersecurity services teams in the fragmented Swedish market Nixu, a focused cybersecurity company, has local operations in Sweden since 2016 when Europoint Networking AB and Safeside Solutions AB joined the company. Nixu’s start in Sweden has been successful and now Nixu continues to expand its operations by acquiring Bitsec AB specialized in digital forensics, penetration testing and IT security services. Nixu’s growth vision is to become a go-to-partner in cybersecurity services for companies headquartered in Northern Europe and the best place to work for cybersecurity professionals. Following its strategy, Nixu has rapidly grown to be over 300 person strong with offices in Finland, Sweden, Netherlands, USA and Romania. In Sweden the team of over 60 cybersecurity specialists can now better deliver Nixu’s holistic cybersecurity services portfolio. Bitsec’s strong technical expertise especially in data breach investigation, where Bitsec founder André Catry is a well-known expert, complements the existing competences of the Swedish team and enables a wider offering. Nixu is now able to offer the Nixu Cyber Defense Center –detection and response service to Sweden with local, Swedish speaking Tier 3 -incident responders on-call. “After establishing Nixu in the Swedish market, we have received a lot of feedback from large enterprise clients who have wishes for a more comprehensive cybersecurity services offering from one partner. Now we are in a unique position to help Swedish clients to implement their new digital services securely and ensure their availability despite the cyber threats. I’m delighted to welcome Bitsec experts to join the Nixu family. I truly believe that the experts of both companies will learn a lot from each other. With this great team in Sweden, we aim to continue our growth and look for new teams and talented individuals to join the family“, says Petri Kairinen, Nixu CEO."The joint company is a great example of merging people and competencies generating further increase of client value. While getting to know the Nixu team it is obvious our organizations carry the same type of cultural background and motivation based upon the passion for cybersecurity and technology. This has me convinced employees from both organizations will significantly benefit from this matchup. We are also now able to offer new services, such as 24/7 detection of incidents, to our clients from Nixu’s existing portfolio. Based on the uptake in client demand, the value to our personnel and increase in services we will be able to jointly offer; I am convinced the new setup is of significant benefit to all involved", says Jesper Svegby, CEO of Bitsec AB.NIXU CorporationFurther information:CEO Petri Kairinen, Nixu CorporationTelephone +358 40 832 1832, e-mail: petri.kairinen@nixu.com CEO Jesper Svegby, Bitsec ABTelephone +46 733 56 54 56, e-mail: jesper.svegby@bitsec.se Distribution:main mediawww.nixu.com/enNixu in brief:Nixu Corporation is a cybersecurity company. We work to improve our clients’ cybersecurity in solution areas of Corporate IT, Digital Business and Industrial Internet. Our clients trust Nixu in projects where developing, implementing or assessing of information security is a must. We ensure the confidentiality of our clients' data, business continuity and ease-of-access to digital services through planning and mitigation of cybersecurity risks.www.nixu.com, www.nixu.com/en/blog and twitter: @nixutigerteamBitsec in brief:Bitsec is a privately owned Swedish company which started in 2006 with offices in Stockholm and Karlstad, and operates in the area of IT & Information security. Our strength lies with our highly competent consultants whom we dare to call some of the best in the world, proven by our track record not only with highly satisfied customers but with numerous final positions in the annual Code Gate competition.We offer a variety of services such as: deep technology analysis of systems and code, incident response, forensics, penetration and 360perimeter analysis.  Since its inception, Bitsec has been working widely throughout the IT security area locally, as well as on the international scene supporting our clients wherever and whenever needed. Our customers ranges from authorities, major international groups as well as medium-sized private companies. Throughout our history we have proven our point: We know what´s going on!www.bitsec.se MyNewsdesk: https://www.mynewsdesk.com/se/bitsec LinkedIn: https://www.linkedin.com/company/bitsec-ab and twitter: @BITSECCYBER

Analysguiden’s analysis is now available in English.

The analysis of Brighter AB, originally published by Analysguiden on the 15th of June 2017, is now available in an English translation. Read the full analysis at Analysguiden . For more information, please contact:Truls Sjöstedt, CEO                Tel: +46 709 73 46 00                Email: truls.sjostedt@brighter.se  Henrik Norström, COO                Tel: +46 733 40 30 45                Email: henrik.norstrom@brighter.se About Brighter AB (publ)    Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on NASDAQOMX First North/BRIG . Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.

New Hybrid Operating Room in Getinge Experience Center, Germany.

June 26, 2017Rastatt, Germany Getinge is pleased to announce the opening of a new modern hybrid operating room (OR) in the Experience Center in Rastatt, Germany. The Hybrid OR – a surgical theatre equipped with advanced medical imaging devices – enables intraoperative 2D and 3D imaging during minimally-invasive surgery. The Getinge Experience Center (formerly the Getinge Showroom) is an international knowledge hub that presents a wide range of products and solutions within a complete, real-world medical setting. This center welcomes over 24,000 healthcare professionals per year. The new Hybrid OR is equipped with a combination of the new ARTIS pheno® robotic C-arm from Siemens Healthineers, the Maquet Magnus Operating Table and associated products (such as the Maquet Moduevo Ceiling Supply Units, soon to be installed). This facility creates a unique environment where visitors can envision the possibilities of intraoperative imaging. The Hybrid OR was officially opened on Tuesday 20 June 2017 by Frédéric Pette, Acting President Surgical Workflows, Getinge and Dr. Heinrich Kolem, President Advanced Therapies, Siemens Healthineers. Frédéric Pette shared the visionary nature of the partnership and the strong focus on research and development. “With Siemens Healthineers we have a partner that has enabled us to upgrade our Hybrid OR with the latest robotic C-arm on the market. The combination of ARTIS pheno® and Maquet Magnus is taking imaging to a new level. And this is just the beginning. Our strategic partnership will lead to more innovative solutions in the near future.” “The last five years of our partnership have shown us that Getinge and Siemens Healthineers share a common vision - bringing imaging systems, robotics and surgery together. Therefore it was an easy decision for us to install one of the first ARTIS pheno® here at Getinge’s Experience Center and make this vision accessible to our customers. It also underlines how valuable this partnership is to us.” Dr. Heinrich Kolem added. About ARTIS pheno® ARTIS pheno® is an angiography system delivering images for individualized preprocedural planning, intraoperative guidance, and immediate assessment. The unique floor-mounted robotic C-arm system allows patients to be treated in a hybrid operating room regardless of their size, condition, or positioning needs, meeting the significant challenges modern minimally invasive treatment poses to imaging systems. About the Getinge Hybrid OR Getinge is a market leader in the hybrid OR market, completing over 900 installations worldwide, and providing the complete range of products including operating tables, surgical lights, ceiling supply units, wall and ceiling elements, anesthesia units, heart-lung machines and OR integration. For further information, please contact Tracey Dawe Director Communications and Congress Management Europe, Middle East & Africa Phone: + 44 77 177 84965 Email: tracey.dawe@getinge.com About Getinge Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving every-day life for people, today and tomorrow.

AGREEMENT TO ACQUIRE MANOR FARM – THE LEADING CHICKEN PROCESSOR IN IRELAND

Scandi Standard AB (publ.) (SCST SS) is pleased to announce that it has entered into an agreement to acquire Manor Farm, the largest chicken processor, and market leader, in the Republic of Ireland (Ireland). The business had net revenues of EUR 164 million and EBITDA of EUR 13 million in 2016. The agreement values Manor Farm at an enterprise value, based on the closing price for the Scandi Standard shares on 26 June 2017, of EUR 94 million. Settlement will be a combination of 6 million Scandi Standard shares (“Consideration Shares”), an earn-out mechanism, cash and the assumption of outstanding interest-bearing debt. Completion of the transaction is subject to customary conditions, including approval of the issuance of the Consideration Shares at an Extraordinary General Meeting of Scandi Standard. The four largest shareholders, representing approximately 29% of Scandi Standard’s share capital, support the transaction. Transaction rationale · Profitable and well-run operations · Clear market leader in a market with strong preference for local produce · Capable and experienced management team with a strong track record · Tangible best practice opportunities identified · Significant EPS accretion · Attractive EV/EBITDA acquisition multiple · Post transaction leverage ratio unchanged · Risk diversification through a new geographical presence About Manor Farm Manor Farm sources and processes approximately 50% of all fresh chicken sold in the Irish retail market and approximately 25% of all chicken consumed in Ireland. The business focuses on fresh products for the retail market, selling to a diversified customer base. The business has its processing plant in Shercock in County Cavan. It has approximately 130 farmers contracted as growers and approximately 43 farmers contracted as breeders. It owns and operates a feed mill, which has revenues of approximately EUR 80 million and produces solely for its contracted growers. In the accounts, feed revenues will be eliminated from Manor Farm’s net revenues. The combined entity generated an EBITDA of EUR 13 million in 2016. Manor Farm employs approximately 850 people. Manor Farm is one of the oldest family businesses in Ireland, tracing its origin to 1775 when the founder, Peter Carton, set up a business in Dublin’s fruit and vegetable markets. Recognising the opportunity for a poultry market, he began trading in all forms of poultry. Since then, the Carton family have continued the business. In 1956, they opened a chicken processing plant in Dublin, introducing modern chicken products to the Irish market, and in 1970 they moved their business to a new custom-built processing plant, which has been expanded and upgraded continually since then. Vincent Carton and Justin Carton are the eighth generation of the family in the business. They succeeded their father, Thomas P. Carton, who was involved in the business for 69 years. Over the past generation, Vincent and Justin and their management team have worked closely with Irish retailers and farmers to create a stable and sustainable supply of Irish produced chicken that meets an increasingly discerning consumer demand. About the Irish poultry market The dynamics of the Irish poultry processing market are very similar to those in the Nordic markets. The market is well consolidated with three domestic players of scale. Manor Farm has a market share of about 50% for fresh chicken products sold through retail in Ireland. As in Scandi Standard’s existing markets, there is a strong preference for domestic produce in the retail channel, and the fresh segment is well developed. Importers distribute mainly to food service, butchers and industrial segments. The consumer market in Ireland is similar to the Nordic markets in terms of size, population and GDP. Leif Bergvall Hansen, CEO of Scandi Standard, states: “I am enthusiastic about the deal as Manor Farm satisfies all of our acquisition criteria. The company has profitability in line with our existing operations, is well run and is the clear market leader in chicken in the Irish retail market. With its capable and experienced management team, the business can be run with a high degree of autonomy whilst additional steps, which have been identified, can be taken to capture the benefits of best practice. As many of our risks are country specific, the acquisition is also likely to reduce our earnings volatility through diversification.” The transaction The deal values Manor Farm at EUR 94 million (Enterprise Value) based on Scandi Standard’s closing share price as of 26 June 2017 (SEK 52.5). Settlement is agreed to consist of the Consideration Shares, equivalent to 9.99% of the current share capital of Scandi Standard; four earn-out tranches with payments calculated on the basis of the EBITDA achieved by Manor Farm in 2017, 2018, 2019 and 2020 respectively, which have a nominal aggregate base amount of EUR 25.4 million; and the balance, EUR 36.3 million, in the form of cash payments and assumption of outstanding interest-bearing debt. Completion of the transaction is subject to customary conditions, including approval of the issuance of the Consideration Shares at an Extraordinary General Meeting of shareholders of Scandi Standard. The transaction is expected to close during the second half of Q3. The vendors of Manor Farm have agreed to a 12-month lock-up on the Consideration Shares commencing from their first day of trading. The first earn-out tranche of EUR 0.4 million will be paid if 2017 EBITDA exceeds EUR 13 million. The three later earn-out tranches, which have a nominal aggregate base amount of EUR 25 million, are subject to adjustment based on the actual EBITDA performance in each of the earn-out years 2018, 2019 and 2020 as compared to the 2016 EBITDA. For the calculation of each earn-out payment, a sliding EV/EBITDA multiple scale is applied, ranging from a minimum multiple of zero to a maximum multiple of 9. The earn-out tranches will be paid upon availability of audited accounts for the relevant year, verifying EBITDA. The agreement includes a provision whereby the vendors of Manor Farm would be eligible for a minimum of the base earn-out amount at maturity of each of the remaining earn-out tranches if there is a change of control in Scandi Standard. Manor Farm has a very experienced management team with a strong track record. Five members of the management team currently own 100% of Manor Farm, and as shareholders in Scandi Standard they will continue to lead and develop the business in alignment with the rest of the Scandi Standard group. Vincent Carton and Justin Carton, who currently hold 85% of the financial interest in Manor Farm, intend to remain as Scandi Standard shareholders over the longer term, and Vincent Carton has agreed to join the Board of Directors of Scandi Standard if proposed by the Nomination Committee and elected by the General Meeting. Leif Bergvall Hansen states: “We are also pleased that the financial criteria are met in terms of expected EPS accretion and an attractive acquisition multiple. Furthermore, the limited upfront cash consideration leaves our leverage ratio largely unaffected by the transaction, which is an important criterion in terms of allowing a competitive direct yield going forward. Finally, the transaction structure secures alignment of interests and clear incentives for management to further develop the business. We look forward very much to being part of the Irish food processing industry and to building on the strong relationships of Manor Farm in that market.” Vincent Carton, CEO of Manor Farm, states: “In considering a succession of ownership for our family business, my brother Justin and I have been determined to find a partner that can continue to build on our strong relationships with customers, employees, suppliers and the broader communities in which we operate. As the next generation of Cartons have chosen to pursue other business interests, we set out to find a partner with high standards, a culture similar to our own and the capability to develop the business to its fullest potential. We believe that Scandi Standard is the ideal partner, and we are delighted to have agreed a transaction structure that allows the current management to remain fully in place and that also allows the Carton family to become shareholders in Scandi Standard. We believe that this arrangement will serve our customers, employees, and suppliers well, and we look forward very much to the next chapter in the history of Manor Farm.”  Preliminary proforma figures and accounting matters  Transaction costs are estimated at a little over 2% of EV, including stamp duty of 1% of the purchase price. The identified improvement potential is partly reliant on capital expenditures and certain measures to align operations with industry best practice. The phasing of such investments and measures will be resolved on a case by case basis within the general planning framework of the Scandi Standard group, and be communicated and accounted for accordingly. Financing The payment of the purchase price will be financed by an issuance of six million shares in Scandi Standard and the cash payment and transaction costs will be financed by a combination of available cash and existing bank facilities. Extraordinary General Meeting (EGM) Scandi Standard’s Board of Directors will shortly call an EGM to seek approval for the transaction through a proposal to authorise the board to issue the Consideration Shares. The date for the EGM is planned to be on or about 15 August 2017. Scandi Standard has approached its four largest shareholders, representing a total of approximately 29% of the current share capital, who support the authorisation for the board to issue the Consideration Shares at the EGM. The EGM resolution will require approval from 2/3 of the votes cast and shares represented at the EGM. Issuance of the Consideration Shares The Board of Directors will resolve to issue the 6 million Consideration Shares following the EGM’s authorisation. The purpose of the issuance is to pay in part for the acquisition of Manor Farm and the shares will be subscribed for by the sellers of Manor Farm. The issuance will result in a share capital increase of approx. SEK 60,000. The issue price for the shares will be approx. EUR 36 million. The Consideration Shares are expected to be issued in connection with closing of the acquisition, i.e. in the second half of Q3. Presentation of the acquisition Scandi Standard will hold a presentation about the acquisition of Manor Farm on Tuesday 27 June 2017 at 09.30 CET. The presentation will be hosted by Leif Bergvall Hansen, CEO and Henrik Heiberg, Head of M&A, Financing and IR. Dial In numbers: Sweden 0850 510 036  United Kingdom 0800 368 0649All other locations + 44 20 3059 8125 The presentation used in the conference call will be published at http://www.scandistandard.com prior to the call. The conference call will also be audio webcasted in “listen-only” mode at the Scandi Standard website. For further information please contact: Leif Bergvall Hansen, CEO of Scandi Standard (+45 22 10 05 44)Henrik Heiberg, Head of M&A, Financing and IR, Scandi Standard (+47 917 47 724) This information is information that Scandi Standard AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 0730 CET on 27 June 2017. ABOUT SCANDI STANDARD AB (publ.) Scandi Standard is the largest producer of chicken-based food products in the Nordic region with leading positions in Sweden, Denmark, Norway and Finland. The company produces, markets and sells ready to eat, chilled and frozen products under the strong brands Kronfågel, Danpo, Den Stolte Hane and Naapurin Maalaiskana. In 2016 Scandi Standard produced approximately 130 million chickens, had net sales of 6,000 MSEK and 1.700 employees. In 2014 Scandi Standard was introduced on the Stockholm stock market. OECD has forecasted that half of the world's protein intake will come from chicken in the year of 2023. Several trends drive the demand, such as:  · Increased health consciousness · Superior environmental profile · Convenient and easy-made · Lower production costs than red meat Scandi Standards strategy for profitable growth is to drive organic growth, increase the cost effectiveness and make strategic acquisitions and partnerships. IMPORTANT INFORMATION This press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares or other securities in Scandi Standard. This press release has not been approved by any regulatory authority and is not a prospectus. This press release contains forward-looking statements which reflect Scandi Standard’s current view on future events and financial and operational development. Words such as "intend", "will", "expect", "anticipate", "may", "plan", "estimate" and other expressions than historical facts which imply indications or predictions of future development or trends, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. The information, opinions and forward-looking statements concluded in this announcement speak only as of its date and are subject to change without notice.

Autoliv and Volvo Cars to team up with NVIDIA to develop advanced systems for self-driving cars

Autoliv and Volvo Car Corporation, with Zenuity, a newly-formed automotive software development joint venture equally owned by Autoliv and Volvo Car Corporation, will work together with NVIDIA to develop next generation self-driving car technologies, with a target to bring level 4 autonomous driving to the market by 2021. As part of the agreement Autoliv, Volvo, and Zenuity will use NVIDIA’s AI car computing platform as the foundation for their own advanced software development, bringing together two of the most respected companies in automotive safety with one of the world’s leading artificial intelligence companies. Jan Carlson, Chairman, President and CEO of Autoliv, said:  “We now have full access to the leading computing platform for autonomous driving. Autoliv, Volvo Cars and NVIDIA share the same vision for safe, autonomous driving. This cooperation will further advance our leading ADAS and autonomous driving product and solution offerings to the market.” “This cooperation with NVIDIA places Volvo, Autoliv and Zenuity at the forefront of the fast moving market to develop next generation autonomous driving capabilities and will speed up the development of Volvo’s own commercially available autonomous drive cars,” said Håkan Samuelsson, President and Chief Executive of Volvo Cars. Jensen Huang, Chief Executive of NVIDIA, said: “Artificial intelligence is the essential tool for solving the incredibly demanding challenge of autonomous driving. We are building on our earlier collaboration with Volvo to create production ready vehicles that will make driving safer, lead to greener cities and reduce congestion on our roads.” Autoliv, Volvo Car Corporation, Zenuity, and NVIDIA will work together to develop systems that can utilize deep learning -- a form of artificial intelligence -- to recognize objects in their environment, anticipate potential threats and navigate safely. These systems can compare real-time situational awareness with a known high-definition map, enabling them to plan a safe route and drive precisely along it, adjusting to ever-changing circumstances. They also perform other critical functions such as stitching camera inputs to create a complete surround-view of the car. The cooperation with NVIDIA will complement Zenuity’s existing mission to provide Autoliv autonomous vehicle related software to third party OEMs using Autoliv’s established and broad sales, marketing and distribution network and to provide Volvo Car Corporation with self-driving software for its own vehicles. Inquiries: Thomas Jönsson, Group Vice President Communications.          Tel +46 (0)8 58 72 06 27

Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

Boston, U.S. and Lund, Sweden — 27 June 2017 — Rhythm and Camurus (NASDAQ STO:CAMX) today announced positive initial results from an ongoing Phase 1A clinical trial evaluating the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide (RM-493), Rhythm’s novel melanocortin-4 receptor (MC4R) agonist in development for the treatment of rare genetic disorders of obesity. The new setmelanotide formulation uses Camurus drug delivery technology FluidCrystal® injection depot. Camurus has granted Rhythm a worldwide license to the FluidCrystal® technology to formulate setmelanotide and to develop, manufacture and commercialize this new formulation that has the potential for once-weekly dosing administered as a subcutaneous injection. Rhythm is developing setmelanotide for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. This ongoing Phase 1A clinical trial is a double-blind, placebo-controlled, single-rising dose study to evaluate the pharmacokinetics and tolerability of three doses of setmelanotide extended-release formulation in healthy obese patients (BMI ≥ 30 kg/m2), with setmelanotide administered by subcutaneous injection. “The initial results from this first trial are impressive and meet our pharmacokinetics and tolerability criteria for a once-weekly formulation of setmelanotide,” said Dr. Keith Gottesdiener, Chief Executive Officer and Chairman of the Board of Directors of Rhythm. “We intend to develop this once-weekly formulation as a product line extension, to improve convenience for patients with genetic deficiencies in the MC4 pathway.” “Reducing the burden of daily injections and contributing to keeping the individual at a healthy weight, is an important step forward that may potentially provide patients with enhanced quality of life,” said Dr. Fredrik Tiberg, President and Chief Executive Officer of Camurus. The U.S. Food and Drug Administration (FDA) granted setmelanotide Breakthrough Therapy Designation (BTD) for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LepR) deficiency obesity. Results from Phase 2 clinical trials of setmelanotide demonstrated significant weight loss and substantial reductions in hunger for patients with POMC and LepR deficiency obesity. Rhythm recently initiated Phase 3 clinical trials for each of these indications. About SetmelanotideSetmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway – a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity. Rhythm recently initiated Phase 3 clinical trials of setmelanotide in POMC deficiency obesity and in LepR deficiency obesity. These are rare genetic disorders associated with severe, early-onset obesity and unrelenting hyperphagia caused by defects in the MC4 pathway that are upstream of MC4R. Initial efficacy data with setmelanotide demonstrate that it has the potential to restore lost function by activating the intact MC4 pathway below the genetic defect in these disorders. Rhythm is currently evaluating setmelanotide for the treatment of the following genetic disorders of obesity: POMC deficiency obesity, LepR deficiency obesity, Prader-Willi syndrome, Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity and POMC epigenetic disorders. About FluidCrystal® injection depotThe FluidCrystal® injection depot delivers therapeutic levels of drug substance over selected extended periods – from days to months – from a single injection. While traditional depot therapeutics comprise complicated microsphere technology, the FluidCrystal® injection depot offers a liquid solution that transforms into a controlled release liquid crystal gel matrix in situ on contact with minute quantities of aqueous fluid at the injection site. The FluidCrystal® delivery system overcomes traditional side effects associated with high initial drug release on injection (drug burst) and poor drug stability by effectively encapsulating the drug compound in the nanopores of the depot matrix throughout the entire process from injection until final degradation. This, together with the ready-to-use product design, makes the system highly suitable for sustained parenteral delivery of peptides and proteins. FluidCrystal® is a registered trademark of Camurus AB. About RhythmRhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class MC4R agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts. For more information, visit www.rhythmtx.com. About CamurusCamurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com. Media contactsFor Camurus:Fredrik Tiberg, President & CEOTel. +46 (0)46 286 46 92fredrik.tiberg@camurus.com Rein Piir, VP Investor RelationsTel. +46 (0)70 853 72 92ir@camurus.com For Rhythm:Adam Daley, Berry & Company Public RelationsTel. +1 212 253 8881adaley@berrypr.com The information was submitted for publication at 08.00 a.m. CET on 27 June 2017.

Combination of Lindorff and Intrum Justitia completed creating the industry leading provider of credit management services

Today, June 27th 2017, the combination of Intrum Justitia and Lindorff has been closed. All subsidiaries of Lock TopCo AS (parent company of the Lindorff Group) are fully owned by Intrum Justita AB (publ). CEO & President of the combined business will be Mikael Ericson, as communicated on June 9th 2017. On June 12th 2017 the European Commission approved the combination of Intrum Justitia and Lindorff. The approval is conditional upon the divestment of Lindorff’s operations in Denmark, Estonia, Finland and Sweden as well as Intrum Justitia’s operations in Norway, as communicated on May 18th 2017. The combination of Intrum Justitia and Lindorff creates a leading provider of credit management services (CMS) with local presence in 23 markets across Europe and a team of around 8,000 employees that are committed to promote a sound economy. “This is a milestone, not only for these two great companies, but for all of the CMS industry. By joining forces, both local and global clients will benefit from our pan-European platform, enhanced service offering, innovative solutions and best in class compliance. I am truly excited that we have come to this day and I really look forward to leading this company,” says Mikael Ericson, CEO & President of the combined company. "I am very pleased that the combination of these two strong companies has now been completed. Together, Intrum Justitia and Lindorff will form a market leader that will be able to deliver significant value to clients, shareholders and society by creating a very well-positioned and respected player in our industry both in terms of skill and geographic spread," says Lars Lundquist, Chairman of the Board in Intrum Justitia. "This combined company will be a leading force in shaping the future of credit management services. Nordic Capital looks forward to continuing to support the combined business as a listed company and sees strong potential for further value creation," says Kristoffer Melinder, Managing Partner, NC Advisory AB, advisor to the Nordic Capital Funds. In connection with the completion of the transaction, the current Board of Directors in Intrum Justitia has, by using the authorization of the Extraordinary General Meeting of December 14th 2016, resolved to issue 59,193,594 new shares at a subscription price of SEK 296.70 per share to the owners of Lindorff, after which they own 45% of the shares in Intrum Justitia, as announced in December 2016. In connection with the share issue Intrum Justitia has issued a prospectus, which will be approved by Finansinspektionen around 28 June 2017. The prospectus will be published on Intrum Justitias website, www.intrum.com. Lindorff will be consolidated into the financial statements of Intrum Justitia from 30 June  2017. This information was submitted for publication, through the agency of the contact person set out below, at 09.30 CET on 27 June 2017. For more information, please contact: Annika Billberg, Communications DirectorTel: + 46 702 67 97 91 About Intrum Justitia:Intrum Justitia offers comprehensive services, including purchase of receivables, designed to measurably improve clients’ cash flows and long-term profitability. Founded in 1923, Intrum Justitia has some 4,200 employees in 21 markets. Consolidated revenues amounted to SEK 6.1 billion in 2016. Intrum Justitia AB is listed on Nasdaq Stockholm since 2002. For further information, please visit www.intrum.com About Lindorff:Lindorff has been in the business of helping people manage credit for over 100 years. Its headquarters are located in Oslo, Norway, the same city as Eynar Lindorff founded the company back in 1898. Today it has 4,400 people in 12 countries across Europe helping customers back to a life of sustainable spending. Nordic Capital Fund VIII is a majority shareholder in the company which offers services within debt collection and debt purchase as well as payment and invoicing services. In 2016 Lindorff generated EUR 647 million in net revenue (2015 EUR 534 million). For further information, please visit www.lindorff.com  About Nordic Capital:Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. The Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory entities in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com    

Triton has signed an agreement to acquire univativ

Frankfurt / Darmstadt (Germany), 27 June 2017 – An affiliate of Triton Partners ("Triton") has signed an agreement to acquire univativ Group (“univativ”), a leading German provider of specialized personnel services. Terms of the acquisition were not disclosed. The transaction is subject to regulatory approval in relevant jurisdictions and is expected to close following receipt of those approvals.   "We look forward to supporting univativ’s management and employees as a stable owner by investing in and supporting the growth and development of the company. Business Services is one of our core sectors where we have built substantial expertise and look forward to working together with the management team and board in building an even stronger company", said Peder Prahl, the Managing Partner of Triton Partners. "univativ Group, as one of the market leader in German speaking Europe, has been building its current presence over the last 20 years. This transaction is an important milestone, enabling us to continue with our strategic efforts. We welcome Triton as a new majority owner and a respected investor who will support us in developing innovative services and executing our plans for further expanding our market positions”, said Martin Ilg, Henning Loof and Olaf Kempin, who are the founders and Managing Directors of univativ. “univativ is a great company with an impressive growth profile and the team is looking forward to partner with management in an effort to further grow the firm. We are happy to see that our recently established dedicated smaller mid cap team has already signed its second acquisition”, added Andi Klein, Investment Advisory Professional and an advisor to the Triton Funds. About univativ Groupunivativ Group consists of two core brands: univativ and provativ. univativ, a personnel service provider that specialises in placing young professionals, has been successfully providing student specialists to more than 250 customers in all sectors. Its talent pool includes around 7,000 students and graduates at around 60 renowned universities. With 14 branch offices in Germany and Switzerland, univativ employs more than 1,200 people. provativ is a personnel service provider that specialised in the placement of experienced, freelance IT experts. provativ has two branches in Germany. For more information: www.univativ.com and www.provativ.de About TritonTriton Partners seeks to invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors.  Triton Partners seeks to contribute to the building of better businesses for the longer term. Triton Partners and its executives strive to be agents of positive change towards sustainable operational improvements and growth. The 29 companies currently in Triton's portfolio have combined sales of around €13.9 billion and around 86,000 employees. Triton Partners has dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey. For further information: www.triton-partners.com  Press Contacts: univativStefanie SuffelPhone: +49 6151 850 45 61 TritonMarcus Brans                                                 Phone: +49 69 921 02204 

Successful prediction of Cancer response to LiPlaCis® in Breast cancer and other tumors by OV’s DRP™ – strong support for randomized Phase 2

“If these early results hold in the completed Phase 2 in Breast Cancer, LiPlaCis would be of substantial benefit to those patients predicted sensitive,” Said Peter Buhl Jensen, Adjunct professor, MD, PhD and CEO of Oncology Venture. “The aim is to develop new effective treatment options for patients with hard to treat cancers guided by our Drug Response Predictor - DRP. Our results support that the LiPlaCis DRP is broadly applicable in Breast Cancer and across several cancer types,” Commented Peter Buhl Jensen “Cisplatin is one of the most active anticancer agents ever developed and LiPlaCis is developed as a new improved cisplatin which we can use with precision for the individual patient. We are of course aware that these are early results which need further validation but they do give us good hope for the ongoing and continued studies of LiPlaCis,” Peter Buhl Jensen further commented.  Data Oncology Venture has now completed analysis of those patients - where tumor tissue was available -  from the dose escalation phase of the LiPlaCis Phase 1/2 trial. A total of 11 patients have been analyzed whereof 3 patients from the Phase 2 part have been included. Patients in ongoing LiPlaCis treatment are not included in the analysis. Of the 11 patients with mixed tumor types (where 8 come from the dose escalation cohort) 2 patients had a Partial Remission (PR) and 4 patients had Stable Disease (SD). The correlation between prediction and response to treatment was 0.5 with a one-sided p-value of 0.06. Due to the small number of patients and mixed tumor types, this is a successful validation of the DRP’s ability to predict response. These early data suggest that patients predicted sensitive to LiPlaCis (top third) have a 67% probability of response, and a median of 18 weeks to progression. Strong support of randomized Phase 2 in Breast Cancer The above data supports the ongoing LiPlaCis development in collaboration with Cadila Pharmaceuticals LTD (“Cadila”) and Smerud Medical Research. Oncology Venture entered a collaboration agreement with Cadila. Cadila invest in kind i.e. in research and development activities of 310 cancer patients and DRP screening of more than 1400 patients. Cadila will perform four (4) Phase 2 trials in Prostate, Head & Neck, Skin and Esophageal cancers and a pivotal randomized clinical Phase 3 trial in metastatic Breast Cancer. A total of 18 million SEK has, as previously communicated, been granted to OV’s LiPlaCis project by Oncology Ventures partner Smerud Medical Research and the EUROSTARS program and Oncology Venture and Smerud now starts the preparation of a randomized Phase 2 in Breast Cancer which is expected to include other European countries. LiPlaCis® Phase 2 for metastatic Breast Cancer (mBC) LiPlaCis is an intelligent targeted liposomal formulation of cisplatin. LiPlaCis has finalized the dose escalation part of the trial and has demonstrated promising activity in patients already in the dose escalation part. LiPlaCis™ is administered intravenously in 3 week cycles on day 1 and day 8. Upon the investigator’s judgement, the patient may continue treatment for more than 3 cycles when benefitting from the study. Response (confirmed PR = Partial Response) has been published for the first DRP-screened patient with a hard to treat metastatic Breast Cancer. LiPlaCis has received status as a phase 2 study by the Danish authorities and i.e. 3 out of 4 in total Danish centers are now active in recruiting 12-15 metastatic Breast Cancer patients screened and expected to be highly likely responders to LiPlaCis. Phase 2 study in metastatic Breast Cancer expected to finalize recruitment in Q3 2017. LiPlaCis® has been registered together with its DRP™ companion diagnostic for an EU-marking. Next step in the regulatory strategy is building a data package for a ‘Pre-Submission meeting’ with the FDA. This is done in collaboration with US-experts. About the Drug Response Predictor - DRP™ Companion Diagnostic Oncology Venture uses the Medical Prognosis Institute (MPI) multi gene DRP™ to select those patients that by the genetic signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased. This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA from the patients biopsies. The DRP™ platform i.e. the DRP™ and the PRP™ tools can be used in all cancer types, and is patented for more than 70 anti-cancer drugs in the US. The PRP™ is used by MPI for Personalized Medicine. The DRP™ is used in Oncology Venture for drug development.   For further information, please contact Ulla Hald Buhl, COO and Or Peter Buhl Jensen, CEOChief IR & Communications Mobile: +45 21 60 89 22Mobile: +45 2170 1049 E-mail: pbj@oncologyventure.comE-mail: uhb@oncologyventure.com About Oncology Venture Sweden AB Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.   This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 27th, 2017

EMA approves the potential to dose every 14 days or longer in updated dosing regimen for Alprolix®

Swedish Orphan Biovitrum AB (publ)  (Sobi™) has received approval from the European Medicines Agency (EMA) to update the dosing information for Alprolix® (eftrenonacog alfa). Alprolix is indicated for treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency), and it can be used for all age groups. The dosing information in the product information now includes that patients on long-term prophylaxis to protect against bleeding and who are well controlled on a 100 IU/kg once every 10 days regimen, might be treated on an interval of 14 days or longer.   “We are very pleased with the approval of the updated dosing regimen for Alprolix that offers the potential to extend the dosing regimen to 14 days or longer based on patient’s response. We are committed to improving the lives of people with Haemophilia B, and consider this an important step forward to reduce the treatment burden”, says Milan Zdravkovic, Senior Vice President, Chief Medical Officer and Head of Research & Development at Sobi._____ About Alprolix®Alprolix® (eftrenonacog alfa) [Coagulation Factor IX (Recombinant), Fc Fusion Protein], is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). While Fc fusion technology has been used for more than 15 years, Bioverativ and Sobi have optimized the technology and are the first companies to utilize it in the treatment of haemophilia. Alprolix is manufactured using a human cell line in an environment free of animal and human additives. Alprolix is approved and marketed by Bioverativ for the treatment of haemophilia B in the United States, Japan and Canada. It is also approved in Australia, New Zealand, Brazil and other countries, and Bioverativ has marketing rights in these regions. It is also authorised in the European Union, Iceland, Liechtenstein, Norway and Switzerland, where it is marketed by Sobi. Allergic-type hypersensitivity reactions and development of inhibitors have been observed with Alprolix in the treatment of haemophilia B, including in previously untreated patients. Note that the indication for previously untreated patients is not included in the EU Product Information.  About haemophilia BHaemophilia B is caused by having substantially reduced or no factor IX activity, which is needed for normal blood clotting.[i]  The World Federation of Hemophilia estimates that approximately 28,000 people are currently diagnosed with haemophilia B worldwide.[ii]  People with haemophilia B may experience bleeding episodes in joints and muscles that cause pain, decreased mobility and irreversible joint damage. In the worst cases, these bleeding episodes can cause organ bleeds and life-threatening haemorrhages. Injections of factor IX temporarily replace clotting factors necessary to resolve bleeding and, when used prophylactically, to prevent new bleeding episodes.i  About the Bioverativ and Sobi™ collaborationBioverativ and Sobi collaborate on the development and commercialisation of Alprolix and ELOCTATE/Elocta. Bioverativ has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory, and has manufacturing responsibility for ELOCTATE and Alprolix. Sobi has final development and commercialization rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets).Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts, USA. During a temporary, transition period, which includes time to allow Bioverativ to establish certain licenses and consents related to ELOCTATE® and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products. About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.  For more information please contact Media relations Investor relations SobiSobi          Linda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor Relations+ 46 708 73 40 95, + 46 +1 347 224 0819, +1 212 5798 697 31 74   0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  ---------------------------------------------------------------------- [i]  World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: January, 13, 2017. [ii]  World Federation of Hemophilia. Report on the Annual Global Survey 2013. Available at: http://www1.wfh.org/publications/files/pdf-1591.pdf. Accessed on: January 13, 2017. 

Eltel divests part of its Communication business in Poland

Today Eltel has signed and closed an agreement with Polish BKJ sp. z o.o. to sell its telecom maintenance service operations in Poland. These operations comprise maintenance of copper networks to the Polish telecommunication operator Orange. In 2016, net sales of these operations amounted to approximately EUR 24 million and employed approximately 950 people. The operations had only marginal impact on Group profitability in 2016. Following the transaction, Eltel will record a capital loss of approximately EUR 1.0 million affecting the EBITA result in the second quarter. This transaction aims to provide better opportunities for Communication to focus on the well performing upgrade operations that show good growth opportunities, especially within the fibre and mobile businesses. Following this transaction, Eltel’s core business in Poland will comprise fibre roll outs and mobile operations within Communication as well as design and build of overhead lines and substations within Power. These operations employ a total of approximately 1,000 people. For further information:Håkan KirsteinPresident and CEOTel: +46 8 585 376 00, hakan.kirstein@eltelnetworks.se About EltelEltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2016, Eltel net sales amounted to EUR 1.4 billion. The current number of employees is approximately 9,500. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

World’s smallest fuel cell charger now even smaller: JAQ Hybrid from myFC debuts at Mobile World Congress Shanghai

Fuel cell charger JAQ Hybrid can both produce and store energy, which gives users complete flexibility and true mobility. It is charged either with myFC’s patented fuel card, using salt and water to produce hydrogen, or through a regular power outlet, depending on access and preference. “With JAQ Hybrid we’ve made the world’s smallest fuel cell charger even smaller and smarter. It’s a big step toward our vision of constantly available green energy. We at myFC are convinced that hybrids are the future of the power bank market, and we aim to lead that development,” says Björn Westerholm, CEO at myFC. JAQ Hybrid is designed by award-winning design agency Aruliden, and will initially be available in three colors: the signature JAQ purple, white/gold, and charcoal black. It delivers an output power of 10.5 W, capacity of 4,000 mAh, and weighs about 200 g. Each card is 1,250 mAh. As the charger can store energy, multiple cards can be used to charge several devices. A power card of 2,500 mAh will be introduced later, using the same standardized interface. JAQ Hybrid is fully compatible with Android and Apple iOS smartphones, tablets and USB 5V devices. It is compliant with international air safety regulations. JAQ Hybrid will be on display at Mobile World Congress Shanghai, June 28-30 at the New International Expo Center, Innovation City, Hall W3, Booth A05.  This information is information that myFC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 01:55 CET on 28 of June 2017.

ExpreS2ion repositions and gains important ground in the fight against cancer through joint venture

AdaptVac now holds a prototype of breast cancer vaccine AdaptVac, a joint venture between ExpreS2ion and NextGen Vaccines ApS (NextGen), is dedicated to become a world leading player in the development of highly competitive vaccines and therapeutics for cancer, infectious diseases and immunological disorders. AdaptVac is a 50:50% joint venture between NextGen and ExpreS2ion and will operate as an independent business unit with costs and profits divided equally between the owners. Initially, AdaptVac will focus on two lead projects within oncology and infectious diseases, respectively. This is based on already established studies performed with the licensed VLP technology, where results have demonstrated safety and efficacy in established animal cancer models, leading to a prototype of a breast cancer vaccine. The second indication is not yet disclosed due to patent considerations, but its market value is in the same range as breast cancer. ExpreS2ion repositions and gains substantial economic boost CEO Dr. Steen Klysner says: “We expect to create substantial value for ExpreS2ion and its shareholders through the AdaptVac joint venture based on its superior technology platform and a high value pipeline. This joint venture represents a new market focus for ExpreS2ion and a strong repositioning potential, as we move from being mainly a service provider to also being a developer of vaccines. Based on the impressive existing results, I am certain that the therapeutic and prophylactic vaccines from AdaptVac will be important value drivers for the company in the future.”  Strong market potential and value Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually and resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) on an annual basis generates global sales of US$ 7 billion. While the decade long leadership by HERCEPTIN is expected to come to a halt in light of patent expiries and the introduction of biosimilars, the product profile of AdaptVac’s lead pipeline candidate has the potential to capture market shares, leading to significant sales levels. ExpreS2ion’s Board of Directors estimates a risk-adjusted net present value (rNPV) of AdaptVac’s two lead projects to be more than 100 mio SEK. The value of the rNPV represents the value from forecasted income from milestone payments and royalties of net sales based on an assessment of projected market size, costs for bringing the product to market, and taking into account the risk associated with currently being in the preclinical development stage.  Certified Adviser Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

Norsk Tipping AS signs a new agreement with Link Mobility AS on mobile communications.

Norsk Tipping has chosen Link Mobility as its mobile communications partner. Link Mobility was given the contract through an open tender competition and the agreement is valid for two years, with the option of renewal for another two years.Norsk Tipping is a government-owned limited company under the direction of the Norwegian Ministry of Culture. The company is assigned by the government to offer games that create excitement and entertainment within responsible limits, with the profits going to good causes. Norsk Tipping has more than 2 million customers and hade over NOK 32 billion in revenue for 2016. All profit from the gaming are distributed between sports, culture and humanitarian / social organizations according to a separate distribution key set by its owner, The Norwegian Government."Norsk Tipping is, after our experience, the first Norwegian company to have conducted a multi-channel tender offering. With this, Norsk Tipping shows that they have a clear mobile strategy that they want to communicate through the channels their customers use and prefer to communicate on, young as old. In addition to SMS, most people use and prefer channels like Facebook Messenger, WhatsApp, E-mail, MMS, App push and Snapchat as a communication platform. In additional to these there will always come new channels like RCS, Joyn, etc.            Link Mobility will at all time provide and deliver on all new channels that Norsk Tipping and other customers would like to use. "Says Ina Rasmussen, Director of LINK Mobility AS "Link Mobility delivered the most economically advantageous offer and won the tender competition among a number of sharp competitors. Communication with customers is very important to us and we are looking forward to working closely with Link Mobility over the next years," says Marit Skaugen Holmberg, Categorical Purchasing in Norsk Tipping AS.LINK Mobility are one of Europe's largest providers of B2C mobile services with a range of solutions for efficient and targeted mobile communications between businesses and their customers. LINK Mobility's parent company LINK Mobility Group ASA is listed on Oslo Stock Exchange."We are of course very happy and proud that Norsk Tipping has chosen LINK Mobility as its supplier and partner in their future mobile communications strategy, we are looking forward to a close and innovative cooperation for many years to come." Says Ina Rasmussen. For further information:  LINK Mobility AS                                Jan Tore Kjær, Director Marketing & Salesjan.tore.kjar@linkmobility.comCell: + 47 9595 3000

SenzaGen signs global distribution agreement with Charles River Laboratories

GARDskin is a genome-based test that – with higher accuracy than the current gold standard test method – reveals whether chemical substances are at risk of causing allergies.   "With this new global distribution agreement, we are linking up with yet another very strong partner for the global launch of GARDskin. Charles River is a leading player in many important geographical markets and in several different industries, and we are looking forward to working together in the commercialization of SenzaGen’s high performing, accurate allergy test," says SenzaGen CEO Anki Malmborg Hager. Charles River Laboratories International, Inc. is a global company that specializes in a range of preclinical laboratory services for the pharmaceutical and biotechnology industries. Among its customers are many of the world's leading pharmaceutical and biotechnology companies, academic institutions and government research centres. The company has more than 11,000 employees worldwide and is listed on the NYSE. For more information Anki Malmborg Hager, CEO, SenzaGen ABEmail: anki.malmborg.hager@senzagen.comTelephone: +46 768 284822 About GARDGARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods. About SenzaGenSenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com 

Additional energy companies join SaltX pilot project - Göteborg Energi and Öresundskraft participate in testing of large-scale energy storage concept

As previously announced, the pilot project will be conducted with leading Swedish energy companies, the research- and knowledge company Energiforsk, technical consultant Sweco and Stockholm University. "The fact that Göteborg Energi and Öresundskraft also participate in the pilot project shows the interest energy companies have in large-scale energy storage and EnerStore. It is important for us to have several energy companies that can contribute with their respective expertise and perspectives. In addition, this broad participation allows for a good dissemination of SaltX worldwide patented energy storage technology," said Karl Bohman, CEO of SaltX Technology. Although Vattenfall hosts the pilot plant, Göteborg Energi and Öresundskraft will actively participate in the pilot project and contribute knowledge and information on the design, construction and evaluation of the pilot plant. Both Göteborg Energi and Öresundskraft will also participate in the SaltX application to the Swedish Energy Agency for external funding. For further information, please contact: Karl Bohman, CEO SaltX Technology, tel: 070 560 02 68 About Göteborg Energi Göteborg Energi - www.goteborgenergi.se – is owned by the city of Gothenburg, and one of Sweden's leading energy company offering electricity and power, district heating, gas, cooling, energy services and urban fiber. About Öresundskraft Öresundskraft - www.oresundskraft.se – is owned by the city of Helsingborg and has approximately 260,000 customers in northwestern Skåne. Öresundskraft provides district heating, electricity and district cooling to gas, broadband and services. About SaltX and EnerStore SaltX has developed and patented a Nano-Coated Salt (NCS) energy storage technology that is applied in the SaltX business area for large-scale energy storage for heat and power generation - EnerStore. By coating the SaltX material with different forms of nanoparticles, more energy can be stored in the salt and corrosion is prevented. The material entails high capacity to store intermittent energy sources such as wind and solar energy, with minimal storage losses and in a cost-effective manner.

Trimb acquires well-established OTC products in Europe

Stockholm, June 28th 2017 – Trimb Healthcare AB (“Trimb”) has acquired a portfolio of well-established European OTC products from Cilag GmbH International and Janssen Pharmaceutica NV (collectively, “J&J”). The products, which include Pevaryl®, Fungoral®, Gyno-Pevaryl® and Epi-Pevaryl®, are based on the anti-fungal substances econazole and ketoconazole and are used to treat common fungal infections of the skin. The acquired territory includes Sweden, Norway, Germany, Switzerland, Austria and other European countries.“This deal with J&J is an important step for Trimb and we continue to strengthen our OTC position in northern Europe. We also strengthen our position in dermatology and we see good synergies with Trimb’s other anti-fungal brands, e.g. Cortimyk® and Nailner®”, said Magnus Kamryd, CEO of Trimb.The purchase price, which was not disclosed, was fully underwritten by Trimb’s lead investor, Avista Capital Partners, a leading private equity firm, and by CVC Credit Partners, the credit management business of CVC.For more information, please contact: Anders Larnholt, VP M&A Trimb     Email:      anders.larnholt@trimb.se Phone:     +46 76 677 64 95 Trimb Healthcare ABTrimb is a rapidly growing OTC and consumer healthcare company based in Stockholm, Sweden. The company’s experience and competencies span across all regulatory classes and most therapy fields relevant to consumer healthcare. Trimb’s products are sold in more than 50 countries and the company has its own go-to-market organization in northern Europe.